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ABSTRACT 
 
 
E. AMANDA SNYDER:  β2- Adrenergic Receptor Modulation of Macrophage Inflammatory 
Mediator Production 
(Under the direction of Dr. Patrick Flood) 
 
 
Research has demonstrated that the complex interaction between the nervous system 
and the immune system plays a critical role in maintaining homeostasis. The nervous system 
is capable of modulating the immune response via activation of β2-adrenergic receptors (β2-
ARs) present on immunocompetent cells.  Because macrophages are major mediators of the 
immune response, several investigators have sought to determine the effect of β2-AR 
stimulation upon inflammatory mediator production by these cells.  Traditionally, scientists 
have regarded β2-AR activity as anti-inflammatory since stimulation of these receptors 
inhibits LPS-induced production of inflammatory molecules.  However, a thorough review of 
existing literature reveals several publications suggesting β2-AR activation may actually have 
pro-inflammatory effects upon macrophage response.  Importantly, β2-AR drugs are often 
used to treat various diseases, including several diseases of inflammatory origin. As a result, 
recognizing the dual immunomodulatory potential of β2-ARs is necessary to fully understand 
the inflammatory impact of β2-AR drugs in therapy. 
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CHAPTER I:  IMMUNE – NERVOUS SYSTEM INTERACTION 
 
 
 
 For centuries, the complex interaction between the immune system and the nervous 
system has been a key area of interest for researchers and clinicians alike.   Over time, an 
abundance of evidence has accumulated suggesting that these two systems are tightly 
integrated and communicate extensively with one another [18, 20, 34, 45].  This interaction 
results in a functional “cross-talk” between the immune and nervous systems that is critical 
for maintaining homeostasis [18, 34, 35, 40, 45, 50].  Indeed, numerous lines of research 
have demonstrated that these two systems communicate via a multifaceted network, and that 
this communication is not only important during periods of health but also during disease 
progression [19, 20, 33, 45, 50].   
 
Historical Perspective of Immune – Nervous System Interactions. 
Though the belief that the mind influences physical illness has existed since the 
earliest days of medicine, the disciplines of neuroscience and immunology developed 
independently for a number of years.  As a result, the first reports directly addressing the 
interaction between the immune system and the nervous system were not published until the 
early twentieth century.  During this time, several seminal papers were published that helped 
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establish the alleged relationship between these two super-systems. These publications 
demonstrated that certain immune organs, such as the lymph nodes and spleen, are 
innervated by the nervous system independently of blood vessels [45, 60]. Scientists 
suspected that, by innervating organs of the immune system, the nervous system could gain 
intimate access to immune cells and influence their activity.   Adding to this preliminary 
evidence, Oliver and Schafer published a paper in 1895 characterizing a dramatic increase in 
blood pressure following the injection of adrenal medullary preparations [18, 45, 47].  
Importantly, the bioactive component in these preparations was identified by Otto von Furth 
as “suprarenin,” which later became known as epinephrine – an important catecholamine of 
the nervous system [18, 45, 62].  Taken together, these early papers provided the necessary 
groundwork to encourage the theory that these two systems are interconnected. 
 During the early twentieth century, Loeper and Crouzon published the first 
paper of its kind to demonstrate the modulatory effect of the nervous system, specifically 
catecholamines, on the immune response.  In this landmark paper from 1904, Loeper and 
Crouzon describe a noticeable leukocytosis, or increase in white blood cells, following the 
subcutaneous injection of epinephrine to humans [18, 41, 45].  In 1914, Frey et. al. published 
a paper that characterized this epinephrine-induced leukocytosis in greater detail.   According 
to this publication, the administration of epinephrine in humans resulted in an early increase 
of blood lymphocytes followed by a delayed increase in granulocytes [18, 26].  Not long 
after these initial reports, Ishigami advanced the field by exploring the effect of the nervous 
system on immune response as it pertains to disease progression.   While treating patients 
suffering from chronic tuberculosis, Ishigami noted a decrease in phagocytic activity of 
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leukocytes during periods of intense stress [18, 36, 45].  This was the first of many papers to 
investigate the effect of the nervous system and stress on disease pathogenesis.  
By the 1950s, improved scientific methods allowed for more advanced research 
involving these interactions.  Due to more sophisticated techniques for separating and 
identifying leukocytes, scientists were capable of reporting more detailed accounts of 
catecholamine-induced leukocytosis [15, 24, 64].  For instance, these techniques led to the 
identification of a specialized subset of lymphocytes termed “stress-lymphocytes,” which 
accompanied the previously recognized increase in “normal” lymphocytes following 
exposure to epinephrine.  These “stress-lymphocytes” were later described as large, granular 
lymphocytes that possessed natural killer activity [15].  Improved separation techniques also 
allowed scientists to determine which leukocyte subsets were primarily responsible for this 
well-documented, catecholamine-induced leukocytosis.  As it turns out, natural killer (NK) 
cells make up the largest subset of cells followed by CD8+ T cells.   Catecholamine-induced 
increases in CD4+ T cells and B cells, though present, are not as dramatic [45].     
As the characterization of catecholamine-induced leukocytosis advanced, the question 
of whether or not this phenomenon could be induced by endogenous sources received added 
attention.   Early publications investigating the effect of acute physiologic and psychological 
stress upon the number and distribution of immune cells described a pattern similar to that of 
exogenously administered epinephrine.  Based on these physiologically relevant 
observations, scientist gained confidence in the ability of endogenous mediators released by 
the nervous system to modulate the immune response [45, 53].  Additionally, advancements 
in scientific technology led to studies exploring the effect of catecholamines and other 
neuroendocrine molecules on cellular immune functions such as proliferation, apoptosis, 
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cytotoxic activity, cytokine production, antibody release, migration, phagocytosis, etc [17, 
27, 30, 31, 63, 64].   
Initially, the majority of the work exploring the immune-nervous system connection 
centered around the modulatory properties of the nervous system with respect to immune 
response.  During the late 1970s and early 1980s, interest in the ability of the immune system 
to modulate the nervous system became more apparent.  It was during this time that 
Besedovsky and colleagues published several important papers demonstrating that the 
immune and nervous systems communicate in a “bi-directional” manner [7, 9, 11, 12, 61].  
As the field progressed, increasing amounts of evidence demonstrated that inflammatory 
mediators, such as cytokines, prostaglandins and chemokines, released by immunocompetent 
cells are able to influence various activities of the nervous system [7, 8, 10, 14, 61]. This 
collection of work established the concept that a biologically functional “cross-talk” exists 
between the nervous and immune systems.     
As indicated by this brief historical review, there has been significant interest in 
understanding the complex interaction between the immune system and nervous system for 
many years.  Currently, much of the work in this field is focusing on the effect of the nervous 
system upon immune response and disease progression.  There is a great deal of attention 
directed toward investigating the effect of catecholamine-induced immunomodulation and 
the progression of various illnesses.  These illnesses include not only neurodegenerative 
diseases such as Parkinson’s and Alzheimer’s Disease but also autoimmune diseases such as 
Rheumatoid Arthritis [19, 20, 33, 40, 45, 54, 56].  
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Nervous System Modulation of Immune Response. 
 Years of research have established several pathways to describe the complex 
communication network that exists between the nervous system and the immune system. As 
mentioned before, this integrative “cross-talk” is essential to maintaining homeostasis.  If any 
of these pathways are interrupted, serious consequences may evolve.  Indeed, disturbances in 
these routes of communication can directly influence various aspects of disease progression 
such as course, duration and severity [17, 19, 32, 52, 55]. 
There are many routes of communication linking the immune and nervous systems 
with one another as shown in Figure 1.1.  This thesis, however, will focus primarily on the 
immunomodulatory effect of the nervous system upon immune response.  More specifically, 
this paper will explore the effect of adrenergic modulation on the inflammatory response of 
macrophages.  Nevertheless, it is important to recognize the multi-factorial communication 
network employed by the nervous system to modulate the immune response.  There are two 
primary mechanisms by which the nervous system sends signals to the immune system:  (1) 
neuroendocrine hormones released via the hypothalamic-pituitary-adrenal (HPA) axis and (2) 
adrenergic catecholamines released via the autonomic nervous system (ANS). These 
mechanisms allow the nervous system to communicate with the immune system not only on 
the local level at various sites of inflammation but also on a systemic level throughout the 
entire body [18, 32-34, 52].   
For the past 50 years, scientists have recognized the effects of the HPA axis on the 
immune system.  It is widely accepted that the HPA axis is the primary regulator of the 
hormonal stress response.  It is also well known that glucocorticoids are the primary effector 
molecules of the HPA axis [17, 29].  These glucocorticoids interact with certain cells of the 
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immune system via glucocorticoid receptors [18-20, 34].  Research has shown that 
stimulation of glucocorticoid receptors can regulate a variety of immune cell functions 
including differentiation, proliferation, cytokine production, immune-cell trafficking and 
migration [3-5].  Although the importance of the HPA axis in modulating the immune system 
is undeniable and deserves a more detailed discussion, the remainder of this thesis will focus 
on catecholaminergic modulation of the immune response via the ANS. 
The ANS, specifically the sympathetic division, is another well-known pathway of 
communication employed by the nervous system to modulate the immune system.  In recent 
years, research has provided ample evidence to substantiate the role of the sympathetic 
nervous system (SNS) in modulating the immune response.  Several studies have revealed 
that the SNS innervates both primary and secondary lymphoid organs, including the thymus, 
spleen and lymph nodes [1, 2, 23].  Upon stimulation, the SNS nerve fiber terminals release 
catecholamines directly into various lymphoid organs – allowing the nervous system to 
interact intimately with cells of the immune system.  Importantly, existing data confirms that 
certain subsets of immune cells express receptors for and can be modulated by 
catecholamines [35, 38, 44, 51].  It is also known that catecholamines, circulating throughout 
the body, can stimulate and influence activity of immunocompetent cells [19, 45]. Based on 
the extensive communication network set forth by the SNS, the nervous system is capable of 
regulating the immune system locally at the site of inflammation, regionally within various 
lymphoid organs and systemically throughout the entire body.  
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Sympathetic Nervous System, Catecholamines and Adrenergic Immunomodulation. 
 The SNS is a division of the autonomic branch of the peripheral nervous system 
(PNS).  As part of the ANS, the SNS and the majority of its activities are not under conscious 
control.  To understand the actions of the SNS, it is imperative to have a basic understanding 
of its anatomic organization.  Briefly, the SNS nerve fibers originate in nuclei located within 
the brain stem.  These nuclei give rise to preganglionic efferent nerve fibers that exit the 
central nervous system (CNS) via the thracolumbar system.  Most of the preganglionic fibers 
of the SNS terminate within the paravertebral chains, which lie on either side of the vertebral 
column.  The postganglionic nerve fibers exit the paravertebral ganglia and go on to 
innervate peripheral tissues throughout the body [11, 18, 21].  The majority of postganglionic 
fibers release norepinephrine and are referred to as noradrenergic fibers [18].  A subset of 
preganglionic sympathetic nerve fibers terminates within the adrenal medulla, which house 
specialized cells known as chromaffin cells.  These chromaffin cells, when stimulated by the 
preganglionic fibers of the SNS, release both epinephrine and norepinephrine [18].   
 As mentioned previously, catecholamines are important effector molecules of the 
nervous system.  Epinephrine (adrenaline), norepinephrine (noradrenaline) and dopamine are 
the most abundant catecholamines of the nervous system [28, 45].  Dopamine is produced 
primarily by neuronal cell bodies located in the substantia nigra and acts as a 
neurotransmitter within the CNS [16, 49].  Epinephrine and norepinephrine can function as 
hormones or as neurotransmitters depending upon the situation.  As hormones, both 
epinephrine and norepinephrine (to a lesser extent) are produced by chromaffin cells of the 
adrenal glands.  During the stress response, epinephrine and norepinephrine are released into 
circulation by the adrenal gland in an approximate ratio of 4:1.  Due to this epinephrine-
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favored ratio, epinephrine is often considered the primary “stress” catecholamine of the 
“fight or flight” response [18, 28, 45].  Both epinephrine and norepinephrine act as 
neurotransmitters within the CNS.  Norepinephrine is also a neurotransmitter of the PNS, 
specifically the SNS, and is released by noradrenergic nerve terminals. Norepinephrine found 
in the blood and tissues surrounding noradrenergic neurons is generally considered the result 
of its localized diffusion out of synaptic regions [21, 28]. 
  As evidenced by the wealth of literature available, catecholamines, such as 
epinephrine and norepinephrine, are capable of modulating the immune response.   These 
catecholamines are the endogenous ligands of specialized receptors known as adrenergic 
receptors (AR).  These receptors are located on numerous cell types throughout the body, 
including cells of the immune system [19, 31, 45].  Studies have demonstrated that 
adrenergic stimulation of specific ARs by both endogenous and exogenous adrenergic agents 
can affect a variety of immune cell functions.  The effect of catecholamines upon immune 
cell distribution and trafficking is the best known account of catecholaminergic modulation 
of immune cell function [18, 45, 64]. As the field has advanced, several publications have 
demonstrated the effects of epinephrine, norepinephrine and an assortment of adrenergic 
exogens on a variety of immune cell parameters. This is best illustrated by the recent increase 
in reports focusing on the ability of catecholamines and other adrenergic agonists to alter 
cytokine production [17, 18, 59].  However, contradicting reports have emerged with regard 
to this line of study as years of research have revealed that catecholaminergic modulation of 
cytokine production can be both pro- and anti- inflammatory in nature depending upon 
certain parameters.  These parameters include not only the type of immune cell and 
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adrenergic receptor that is stimulated but also the duration of adrenergic exposure [32, 37, 
45].    
Adrenergic Immunomodulation in Health and Disease. 
Though many theories have evolved to explain the exact role of catecholaminergic 
modulation upon the immune response, most would agree that this line of communication is 
a vital part of maintaining homeostasis.  Indeed, the tightly regulated interactions between 
the immune system and nervous system are required for maintaining health as well as for 
preventing disease.  Disturbances in this regulatory system lead to severe changes in the 
susceptibility and pathogenesis of a whole host of illnesses.  As expected, research in this 
area has become increasingly important as understanding this interaction can lead to 
improved management of numerous diseases.  
The initial studies exploring the effect of adrenergic immunomodulation took place in 
healthy subjects. As described earlier, this work focused primarily upon characterizing the 
effect of catecholamines upon immune cell mobilization during epinephrine-induced 
leukocytosis [18, 19].  Researchers also used immune cells from healthy subjects to identify 
and loosely characterize the effect of adrenergic stimulation on proliferation, differentiation, 
cytokine production and expression of various surface molecules [18, 25, 35, 38].  More 
revealing information was collected when scientists turned their attention toward identifying 
the physiologic significance of catecholaminergic modulation during pathological conditions 
such as systemic inflammation, hemorrhagic shock and sepsis. 
Aside from their immunomodulatory activities, research has demonstrated that 
adrenergic agonists possess a wide range of physiologically relevant effects within the human 
body.   For years, scientists have known that epinephrine and norepinephrine are involved in 
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regulating autonomic activities within the body, especially during the “fight or flight” 
response.  It is also widely accepted that adrenergic stimulation of the appropriate AR can 
influence blood pressure, airway reactivity, metabolic function, etc.  Based on these facts, 
adrenergic drugs have been used to selectively treat conditions such as asthma, hypertension, 
cardiac disease, severe burns, shock and sepsis [19, 45].  The idea of studying adrenergic 
immunomodulation during disease pathogenesis originally arose from the fact that adrenergic 
drugs are commonly used to treat chronically ill patients [33, 40].  The idea behind these 
studies was to determine whether or not exposing the body to adrenergic agents administered 
to treat other conditions would alter the inflammatory response and/or exacerbate disease 
state.  For instance, many investigators have focused on defining the immunomodulatory 
effect of adrenergic stimulation during shock and sepsis.  Aside from the fact that circulating 
catecholamine levels rise during instances of shock and sepsis, adrenergic drugs are often 
administered to stabilize certain conditions such as irregular cardiac function and blood 
pressure.   Data show that, in septic patients, adrenergic stimulation is capable of modulating 
the release of both pro- and anti- inflammatory cytokines [18, 48].  In fact, it has been 
suggested that the anti-inflammatory nature of β-AR stimulation may be the cause of 
immune response dysregulation that is often noted late in septic shock [6, 48].  This research, 
along with research investigating other conditions that require the use of adrenergic therapy, 
has promoted awareness of the immunomodulatory consequences of administering 
exogenous sources of adrenergic agonists and/or antagonists during disease.  
It did not take long for the field to recognize the importance of understanding the role 
of adrenergic modulation in regard to disease susceptibility.  Early research demonstrated 
that aberrant sympathetic activity affects immune response, thus influencing the outcome and 
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susceptibility of various disease processes.  Studies have shown that unregulated ANS 
function is associated with certain autoimmune diseases such as rheumatoid arthritis [13, 42].  
For example, a study by Felten and colleagues demonstrated that chemical denervation of 
noradrenergic lymph node fibers resulted in increased inflammation and enhanced arthritic 
disease severity [22].  The systemic depletion of noradrenergic activity, on the other hand, 
led to decreased joint destruction in addition to decreased inflammation [19, 42, 46].  
According to existing literature, noradrenergic innervation by the SNS has a dual modulatory 
effect on inflammation and subsequent disease progression [43].  Studies have also been 
done exploring the effect of exogenously administered catecholamines upon the initiation, 
progression and severity of various disease processes.  Staub and colleagues explored the 
immunomodulatory effects of catecholamines upon inflammatory joint disease.  Results from 
this research demonstrated that catecholamines released by the SNS exhibited a dual 
immunomodulatory profile.  During the early stages of joint disease, catecholamines 
appeared be pro-inflammatory in nature.  However, during late stage joint disease, 
catecholamines are capable of reducing inflammation.  These data, in conjunction with other 
reports, suggest catecholamines and exogenously administered adrenergic drugs have varying 
effects on inflammation and disease progression [57, 58].  Therefore, recognizing the dual 
capabilities of adrenergic agents is very important when considering the efficacy of using 
adrenergic drugs as a form of therapy for treatment of any disease. 
 
Summary. 
Understanding the complexity of the “bi-directional” communication network that 
nature has established between the nervous and immune systems has been a topic of interest 
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for many years.  The nervous system has several mechanisms by which it communicates with 
cells of the immune system.  The immune system, in return, employs a variety of 
inflammatory mediators to communicate with the nervous system. Research has 
demonstrated repeatedly that this interaction is a vital part of maintaining homeostasis.  This 
thesis will focus on the interaction between the SNS and the immune system.  More 
specifically, this thesis will address the role of catecholamines in modulating the 
inflammatory response as it pertains to macrophage response.  Nevertheless, it is important to 
acknowledge the complex interactions that exist between these two super-systems, and how 
these interactions influence the immune system during periods of health and disease.  
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FIGURE 1.1 
FIGURE 1.1 –  Bi-directional Communication Network of the Immune and Nervous 
Systems.   As shown by this diagram, these two super-systems interact via a complex, multi-
faceted  communication network.  This biologically relevant “bi-directional” interaction is 
essential to maintain homeostasis  [18, 39].  
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CHAPTER II:  β2 – ADRENERGIC RECEPTORS  
 
 
 
Adrenergic receptors (AR), also referred to as adrenoceptors, are a class of 
membrane-bound receptors that are widely dispersed throughout the human body.  These 
receptors, whose endogenous ligands are epinephrine and norepinephrine, are found on a 
variety of cell types including cells of the immune system [5, 9, 22, 45].  These receptors are 
often considered the reactive components of the effector tissues in which they reside due to 
their response to signals received from postganglionic fibers of the SNS.  In the case of 
immune cells, adrenergic stimulation can modulate cellular immune function, which 
ultimately influences the immune response [22, 71]. The contents of this chapter will provide 
a general overview of adrenoceptors, specifically β2 -ARs. 
 
Adrenergic Receptor Overview.  
Adrenoceptors are a type of G protein-coupled receptors (GPCR) that bind to and are 
activated by catecholamines in addition to numerous exogenously administered adrenergic 
drugs.  Aside from rhodopsin, ARs are the most extensively studied group of GPCR and are 
often used as a model to investigate GPCR signaling mechanisms [20, 76].  In 1948, Ahlquist 
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differentiated the AR family into two major classes, alpha (α) and beta (β) adrenoceptors, 
based on their pharmacological response to various adrenergic activating and blocking agents 
[1, 7].   Twenty years later, Lands and colleagues used techniques similar to those of 
Ahlquist to subdivide β-ARs further into β1 and β2 subtypes [41].  More recently, in the mid- 
to late- 1980s, a third subtype of β-AR was identified.  This subtype is now known as the β3-
AR [35, 81].  During the 1970s, research demonstrated that α-ARs could also be broken 
down into two distinct subgroups. The initial distinction between α-AR subtypes was based 
entirely on anatomical location.  Based on this classification scheme, α−ARs located on the 
pre- junctional synapse were termed α2-ARs while α−ARs located on post-junctional 
synapses were called α1-ARs.  Experiments using adrenergic agonists and antagonists 
extended the division of α−ARs to include functional differences as well [8, 74].  As time 
progressed, advancements in the pharmacological tools available for studying drug-receptor 
interactions, such as radioligand-binding assays, led to the identification of additional 
subtypes of both α1-ARs and α2-ARs.  The development of certain molecular biology 
techniques has also influenced the classification and description of the adrenergic subtypes.  
For instance, recombinant DNA and cloning techniques have been highly instrumental in 
identifying functional characteristics of AR subtypes.  Additionally, the use of homologous 
mRNA hybridization techniques has advanced the field by aiding in the identification of AR 
subtypes located throughout the body [7, 12, 44].  Ultimately, as illustrated by Figure 2.1, the 
original classification system, as described by Ahlquist in 1948, has been refined and 
additional subtypes have been identified [43, 45].  The current consensus regarding the 
nomenclature of the AR family is as follows:  α1A, α1B, α1D, α2A, α2B, α2C, β1, β2 and β3 [7, 
8]. 
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Although primarily characterized by differences in function and distribution, research 
has demonstrated that members of the adrenergic family of receptors share several 
similarities with respect to structural properties.  All of these receptor subtypes are composed 
of a single polypeptide chain that is approximately 400 to 500 amino acid residues in length.  
The primary structure of all AR receptors contains seven stretches of hydrophobic amino 
acid residues.  These highly conserved hydrophobic stretches correspond to seven alpha-
helical transmembrane regions that span the lipid bilayer of the cell upon which the receptor 
resides [9, 43, 44].  As a result, all ARs have three intracellular and three extracellular loops.  
Each AR possesses an extracellular N-terminal domain and an intracellular C-terminal 
domain.  Both of these terminal domains are of variable length and sequence depending on 
AR subtype [44, 77].  The extracellular and transmembrane domains are responsible for 
forming and stabilizing the ligand-binding pocket.  The intracellular regions associate with 
G-proteins, which are coupled to different signaling cascades [45, 63].   Activation of these 
second messenger systems can lead to a variety of outcomes including intracellular Ca2+ 
release, ion channel/pump activation, kinase activation, protein phosphorylation and gene 
transcription [31].  It is important to note, although similar in structure, each AR subtype 
varies not only in their specificity for certain ligands but also in their coupling to G-proteins 
and subsequent second messenger signaling systems.  Moreover, recent data suggests that 
individual AR subtypes are not limited to one specific G-protein but can bind to multiple G-
proteins or none at all to activate different signaling cascades [30, 79].  Based on their 
diverse nature, the adrenergic family of receptors is capable of mediating a wide range of 
physiologically relevant activities throughout the human body including the inflammatory 
immune response. 
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Distribution and Physiologic Relevance of Adrenergic Receptors. 
 As mentioned previously, ARs mediate the highly complex biologic functions of both 
epinephrine and norepinephrine.  To do this, ARs are distributed extensively throughout the 
body [7].  Historically, each subclass of adrenoceptor has been primarily associated with a 
prototypic tissue as shown in Figure 2.2 [44, 77].  For instance, while β1-ARs are considered 
adrenoceptors of the heart, β2-ARs and β3-ARs are most often associated with lung and 
adipose tissue respectively [77].  However, adrenoceptor subtypes are not limited to the 
tissues with which they are most often recognized.  This fact is very important, especially for 
the purpose of this thesis, as ARs can be found on various subsets of immunologically 
competent cells [63]. 
Physiologically, the activation of these receptor subtypes is important in both health 
and disease.  For instance, ARs are involved in maintaining proper blood pressure, 
myocardial contractile force and rate, and airway reactivity [9, 63].  In a very general sense, 
α-ARs mediate excitatory functions, such as vasoconstriction and pupil dilation. β-ARs, on 
the other hand, typically regulate inhibitory functions including vasodilation and 
bronchodilation.  These excitatory and inhibitory guidelines do not always hold true.  A 
prime exception to this rule is the excitatory role of β-ARs in regulating cardiac function 
[66].  During times of illness, adrenergic responses can be manipulated via the administration 
of adrenergic drugs to alleviate symptoms.  Adrenergic therapy is most notably used for 
conditions such as asthma, angina and hypertension [35, 43].  Although manipulation of AR 
activity can be an effective means of treating many illnesses, recent research has shown that 
adrenergic therapy may exacerbate certain disease processes including rheumatoid arthritis, 
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chronic obstructive pulmonary disease and asthma [53, 79].   As a result, AR activation must 
be tightly regulated and carefully manipulated at all times.  
Years of research have focused on exploring the role of ARs during periods of health 
and disease.  In the past, due to limitations surrounding the availability of subtype-specific 
ligands, scientists were hindered in their ability to determine the precise physiologic role and 
therapeutic potential of each AR subtype.  With the advent of gene-targeted mice, however, 
investigators are better able to identify the physiologic functions of each subset [13, 66, 74].  
By combining the use of gene-targeted mice and available subtype-selective ligands, the 
ability to determine the biological effects of AR subtype stimulation has improved 
drastically.  For example, because of these techniques, α1-ARs are now recognized as the 
primary “cardiovascular regulators” of catecholamine activity.  Indeed, members of the α1-
ARs subtype are involved in regulating cardiac growth and contractibility [58, 74].  Studies 
have also shown that α1-AR subtypes are found throughout the vasculature of the body and 
are involved in regulating contractibility of blood vessels in response to catecholamines [14, 
66].  Gene-targeted mice and subtype-specific adrenergic ligands have also been used to 
study the physiological role of α2-ARs and β-ARs.  Research investigating the physiologic 
role of β2-ARs located throughout the respiratory tract has demonstrated that these receptors 
are highly instrumental in regulating airway reactivity.  Based on the knowledge that β2-AR 
activity results in dilation of the bronchial passages, β2-AR agonists are often used to treat 
patients with asthma [2, 16, 80].  A detailed account of each subtype and its physiologic 
relevance is beyond the scope of this work and has been reviewed thoroughly by other 
authors [7, 14, 66].  Nevertheless, it is important to acknowledge the fact that ARs participate 
in a wide array of physiologically relevant functions.  By understanding their role in health, it 
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is possible to manipulate the appropriate AR subtype in an attempt to treat and/or prevent 
certain disease processes. 
 
β 2 – Adrenergic Receptor Overview. 
Since understanding the β2-ARs is a critical component of this thesis, the remainder 
of this chapter will address this particular subset of AR.  The β2-AR is perhaps the most 
studied member of the adrenergic family of receptors.  With regard to physiological 
relevance, the β2-AR is known to influence a variety of biological functions.  Most often, β2-
ARs are associated with their role in regulating the smooth muscle of the airway and 
vasculature.  Over the past three decades, the immunomodulatory properties of β2-ARs have 
gained added attention.  Importantly, adrenoceptors of the β2 subtype have been identified on 
several immunocompetent cell types and are known to influence the inflammatory immune 
response of these cells. 
Over time, research has determined that the gene for the human β2-AR is located on 
the long arm of chromosome 5 (5q31 - 32) and codes for an intron-less gene product of 
approximately 1,200 base pairs (bp) in length [35, 47].   Upon translation, the β2-AR is made 
up of 413 amino acid residues with a mass of approximately 46,500 Daltons (Da) [35, 42].   
As shown in Figure 2.1, there are three major β-AR subtypes (β1, β2 and β3); each of which 
has been identified through a combination of biochemical and pharmacological techniques 
[7].  More recently, evidence has accumulated suggesting there may be a fourth subtype (β4), 
but additional research must be done to confirm these reports [35, 38].  Some studies suggest 
the β4-AR is actually an artifact that represents a specialized state of the cardiac β2- AR [2].   
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β 2 – Adrenergic Receptor Structural and Functional Domains. 
The β2-AR, like all GPCRs, is often referred to as a serpentine receptor because of the 
way they “snake” through the plasma membrane for a total of seven times.  As illustrated in 
Figure 2.3, the β2-AR possesses seven α-helical transmembrane-spanning domains, which 
give rise to three extracellular and three intracellular loops. Moreover, the amino-terminus of 
the β2-AR is located extracellularly while the carboxyl terminus is found in the intracellular 
compartment of the cell [35].  
There are several post-synthetic modifications that are important to note with regard 
to β2-AR structure.  The human β2-AR possesses three sites of N-linked glycosylation 
located at amino acids 6, 15 and 187.  Though the role of these N-linked sugars has not been 
fully defined, research has indicated these sugars are not involved in ligand-binding [18, 75].  
Several lines of research have demonstrated the presence of these carbohydrate moieties are 
important for receptor trafficking as their absence results in reduced β2-AR expression at the 
cell surface [10].  These post-translational modifications are believed to be important not 
only for proper insertion of the receptor into the membrane but also for receptor trafficking 
following agonist exposure [35, 59, 67].  Another important modification of the human β2-
AR is the palmitoylation of the cysteine residue located at position 341.  It is believed that 
this palmitoylated cysteine residue serves to anchor the carboxy-terminus to the plasma 
membrane [62].  Furthermore, research has demonstrated that palmitoylation of this residue 
contributes to the ability of the receptor to stimulate adenylyl cyclase following ligand-
receptor interaction [60, 62].  The region located between the palmitoylated cysteine and the 
final transmembrane-spanning region is α-helical in structure and is often referred to as the 
fourth intracellular loop [35].  Disulfide bonds are the final post-synthetic modification of 
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interest.  Studies have revealed that four extracellular cysteine residues (Cys106, 184, 190, 191) are 
capable of participating in disulfide bond formation.  These disulfide linkages are thought to 
play an important role in stabilizing the ligand-binding pocket of the β2-AR.  Research 
employing amino acid residue substitution and site-directed mutagenesis techniques has 
demonstrated that alterations in any one of the four extracellular cysteine residues mentioned 
above result in lowered ligand binding and/or agonist-receptor specificity [19, 24, 68]. 
 Many of the structural properties of the β2-AR mentioned above are important 
contributors to receptor function.  One of the major functional domains of the β2-AR is the 
ligand-binding pocket, which is formed by the seven α-helical transmembrane domains.  As 
indicated earlier, the cysteine residues of the extracellular domains help stabilize this binding 
pocket via the formation of disulfide bonds.  Other than aiding in stability, the extracellular 
domains play a minimal role in ligand binding [9, 10, 13, 30].   Furthermore, the interruption 
or removal of the amino- and/or carboxy- terminal domains has little effect upon receptor-
ligand binding [18, 70].  The current model describing the active site of the ligand-binding 
domain has it located approximately one-third of the way into the receptor core [35].  The 
use of site-directed mutagenesis has identified several important residues critical for ligand 
binding within the active site.  As shown in Figure 2.3, these residues are as follows:  the 
aspartate residue located in the third transmembrane domain (Asp113); the two serine residues 
found in the fifth transmembrane spanning region (Ser204 and Ser207); the asparagine residue 
in the sixth domain (Asn293) [35, 51].  These four amino acid residues are thought to form 
bonds with the functional groups of the β2-AR ligand and anchor the ligand within the 
receptor core [68, 78].  At this point, it is important to remember that ligand-receptor 
interaction is also influenced by the structure of the β2-AR ligands themselves [35, 68].   
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 The intracellular domains of the β2-AR give also rise to several important functional 
domains.  These domains are involved in G-protein coupling, phosphorylation reactions and 
receptor desensitization.   As shown in Figure 2.3, the amino acid residues of the amino- and 
carboxy- regions of the third intracellular loop and the amino-portion of the carboxyl 
terminus are involved in coupling to G-proteins [35, 68].   The cytoplasmic regions are also 
involved in functional regulation of β2-ARs signaling.  Certain residues located throughout 
these intracellular regions are involved in receptor desensitization.  Receptor desensitization, 
in this case, refers to the process by which the functional interaction between the β2-AR and 
important molecules of the signaling cascade becomes impaired.  The purpose of receptor 
desensitization is to prevent overstimulation of the β2-AR in the presence of excessive 
receptor ligand.  This process occurs via receptor phosphorylation, receptor internalization 
and/or receptor uncoupling.  Importantly, receptor uncoupling refers to the uncoupling of the 
β2-AR and its second messenger system.  Phosphorylation of β2-AR can occur at various 
serine and threonine residues located throughout the third intracellular loop and the carboxy-
terminal domain [15, 35].  Several kinases are involved in β2-AR phosphorylation and 
desensitization.  Protein kinase A (PKA) is perhaps the most recognized kinase involved in 
this process.  G protein-coupled receptor kinases (GRKs) can also play a role in β2-AR 
desensitization [4, 52].  It is important to note that, while both PKA and GRKs lead to 
receptor desensitization, they each do so in a different manner.  For instance, GRKs can only 
phosphorylate ligand-bound receptors and require an accessory protein, known as β-arrestin, 
for desensitization [46, 52].  PKA, on the other hand, can phosphorylate the β2-AR in the 
absence of ligand.  Moreover, PKA does not require an accessory molecule and can directly 
impair β2-AR activity [31].  Increased phosphorylation by PKA or GRK plays an important 
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role in agonist-induced receptor uncoupling.  This receptor uncoupling initially leads to rapid 
desensitization and translocation of the β2-AR into endocytic vesicles.  Within the endocytic 
vesicles, the receptors are typically dephosphorylated and recycled back to the cell surface.   
With time, some receptors fail to be recycled and are sorted into lysozomal vesicles where 
they are degraded.  This, in conjunction with decreased gene transcription, leads to a 
noticeable downregulation of β2-ARs on the cell surface [4, 31, 37].  
 
Signaling mechanisms of the β 2 – Adrenergic Receptor. 
 To better understand the effects of β2-AR stimulation on macrophage response, it is 
important to have a basic understanding of β2-AR signaling mechanisms.  The accepted 
dogma surrounding β2-AR signaling states that β2-AR activation leads to the increase in 
cyclic adenosine monophosphate (cAMP).   As shown in Figure 2.4, this increase is due to 
the activation of adenylate cyclase by the α-subunit of the receptor-associated Gs-protein.  
Once activated, adenylate cyclase catalyzes the conversion of adenosine triposphate into 
cAMP.  At this point, the increase in cAMP leads to the stimulation of PKA [35, 51, 68].  
Though the majority of β2-AR mediated signaling occurs via Gs-proteins and subsequent 
cAMP-dependent mechanisms, there is evidence of other signaling schemes [30, 51, 77, 79].  
The most notable alternative signaling pathway is the Gi-dependent pathway that results in 
the activation of the mitogen-activated protein kinase (MAPK) pathway [3, 55, 79].  This Gi-
dependent pathway requires the phosphorylation of the β2-AR by PKA and is mediated by 
the βγ-subunit of the associated G-protein.  This subunit, along with β-arrestin, serves as a 
scaffold for other signaling molecules such as SOS, cSrc, RAS and Raf [17, 31].  Recent data 
suggests that the MAPK pathways can also be activated by Gs-dependent mechanisms.  This 
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signaling pathway is complex but ultimately leads to MAPK activation via the B-raf 
signaling cascade [21, 33, 79].   Additionally, some studies have shown that β2-AR signaling 
can occur via G-protein independent mechanisms [30, 79].  Without a doubt, the complexity 
of the β2-AR signaling mechanisms is mirrored by the diverse role of these receptors.  
Additional discussion regarding β2-AR signaling that is specific to macrophage 
immunomodulation will be discussed in chapters four and five.   
 
β 2 – Adrenergic Receptor Ligands:  Agonist, Antagonists and Inverse Agonists. 
 Traditionally, the “lock and key” theory of receptor-ligand binding was used to 
describe agonist activation of β2-ARs.  This theory proposed the β2-AR agonist would bind 
the receptor in such a way that the receptor would adopt a conformation that is better suited 
to associate with Gs [51, 57, 61].   Recent research, however, suggests that the receptor 
actually “toggles” between different conformational states in the absence of β2-AR ligand 
[64].   Indeed, several lines of research indicate that GPCRs, like β2-ARs, may be “active” 
even in the absence of receptor agonist [73].  Under resting conditions, the active and 
inactive states are in equilibrium with the inactive state predominating.  β2-AR agonists are 
believed to exert their effects by binding to and stabilizing the active form of the receptor.  
Antagonists of the β2-AR, on the other hand, preferentially bind to the inactivated form of the 
receptor – thus moving the equilibrium further away from the active form of the β2-AR [36, 
57].  Technically, β2-AR agonists and antagonists should not be thought of as competing for 
the same receptor.  Instead, these ligands bind to different forms of the β2-AR and shift the 
receptor confirmation equilibrium in their favor.  
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 As described earlier, studies using site-directed mutagenesis techniques have 
identified important regions of the β2-AR protein for ligand-binding.  Based on these studies, 
a model has emerged that places the ligand-binding domain within the hydrophobic core of 
the β2-AR protein [33, 48 64, 74].   The molecular structure of the β2-AR ligand determines 
the way in which it interacts with the receptor and its binding domain.  For instance, 
hydrophilic agonists are able to access the β2-AR binding site directly from the aqueous 
extracellular region.  These hydrophilic agonists are often referred to as “short-acting” 
agonists due to their direct access and rapid onset of action.  Those agonists that are referred 
to as “long-acting” are typically lipophilic and are readily taken up into the cell membrane.  
Once within the cell membrane, the β2-AR agonist slowly leaches out into the active site of 
the receptor [35, 36].  Furthermore, like most biological systems, β2-ARs are stereo-specific.  
In recent years, several studies have shown that stereo-specificity influences ligand-binding 
and functional responses of β2-ARs.  According to most data, activity of β2-AR ligands lie 
primarily in the R-enantiomer [34, 37].  Importantly, current research suggests that 
stereoselectivity is an influential determinant regarding the immunomodulatory effect of β2-
AR stimulation upon macrophage response [34, 36].    
 As the concept of a spontaneously active β2-AR evolved, so did the ideas surrounding 
classification of receptor ligands.  Adrenergic drugs were originally classified as full 
agonists, partial agonists or antagonists.  Based on the idea that there are multiple states of 
receptors, this classification system seemed over-simplified [39].  As a result, the idea of 
inverse agonism developed.  Inverse agonism is defined as the ability of a ligand to reduce 
the basal level of signaling activity following receptor-ligand binding.  Prior to the 
introduction of inverse agonists, antagonists were believed to have no effect of their own.  
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Instead, these ligands functioned only to prohibit agonist activation of the receptor.   As 
techniques advanced, scientists were able to show that some adrenergic agents are capable of 
reducing basal β2-AR activity.  Subsequently, these drugs were placed in the inverse agonist 
category of β2-AR ligands [11, 65].  With the increased knowledge regarding inverse 
agonists, the classification system used to identify receptor ligands has been modified as 
follows:  full agonist, partial agonist, full inverse agonist, partial inverse agonist and 
antagonists.  Based on the current classification system, a β2-AR antagonist is one that is 
unable to modify constitutive receptor activity alone but is able to block β2-AR agonist-
induced activity [65].  Finally, it is important to note that the concept of inverse agonism is 
relatively new.  As a result, very little research has explored this concept with respect to the 
immunomodulatory properties of this class of adrenergic drugs.   
 
β 2 – Adrenergic Receptor Gene Polymorphisms. 
 As mentioned earlier, β2-ARs modulate numerous physiologically relevant events in 
the human body.  In recent years, research has identified several polymorphisms of β2-ARs.  
Studies have shown that some of these polymorphisms affect the biological responses of β2-
ARs [49].  With regard to clinical relevance, these polymorphisms are believed to influence 
airway responsiveness and bronchodilation following exposure to β2-AR agonist.  It is also 
possible that these polymorphisms influence the modulatory properties of β2-AR with regard 
to immune response.  
 Because there are two genes for the β2-AR, an individual can be either heterozygous 
or homozygous for a particular polymorphism.  A total of nine different single base 
substitutions have been identified in the coding region of the β2-AR.  Due to the redundancy 
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of the genetic code, five of these polymorphisms are degenerate and are often considered 
“clinically silent” [25, 48, 69].  However, several papers have been published in recent years 
suggesting that these silent (or synonymous) mutations may actually influence receptor 
function [6, 48, 49, 50].   Research has shown that the remaining four polymorphisms result 
in alterations of the β2-AR amino acid sequence.  Three of these polymorphisms are known 
to influence β2- AR functionality both in vivo and in vitro [6, 48]. These polymorphisms are 
located at position 46 (Arg16Gly), 79 (Gln27Glu) and 491 (Thr164Ile) within the coding 
region of the β2-AR [6, 50].  The fourth SNP located at position 100 (Val34Met) is extremely 
rare and is regarded as having minimal (if any) effect upon receptor function.  As a result, 
very little research has been done exploring this particular polymorphism [6, 48, 49]. 
 Early studies investigating β2-AR polymorphisms focused on the single nucleotide 
polymorphism (SNP) located within codon 16.   As shown in Figure 2.3, this polymorphism 
is found in the extracellular amino terminus of the β2-AR and results in either arginine or 
glycine (Arg  Gly) at residue position 16.  In vitro studies using site-directed mutagenesis 
of the wild type (wt) β2-AR have demonstrated that receptors with the Arg  Gly 
polymorphism do not exhibit altered binding of receptor ligand or activation of adenylate 
cyclase [28].  However, this polymorphism appears to influence receptor desensitization and 
trafficking.  Following exposure to receptor agonist, the Gly 16 form of β2-AR is 
downregulated to a greater degree than the Arg 16 variant [69].  Clinically, the Gly 16 
receptor polymorphism has been linked to increased airway reactivity [32].  Furthermore, 
several studies have focused on examining the effect of the Arg16Gly polymorphism on 
cardiac responsiveness.  For years, it has been accepted that stimulation of human β2-ARs 
increases hearth rate and contractility.  Data exploring this topic indicates that there is no 
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difference with respect to heart rate and contractility between individuals with wt β2-ARs and 
those with Gly 16 β2-ARs [48, 49].   Although the Arg 16 variant is considered the wt 
receptor, the occurrence of the Gly 16 form is higher in Caucasians.   The allelic frequency is 
35% and 65% for the Arg 16 and Gly 16 variants respectively [27, 35]. 
 The second SNP of interest is positioned within codon 27 of the β2-AR.  This 
polymorphism results in a receptor possessing either glutamine or glutamate (Gln  Glu) as 
the 27th amino acid residue [35]. The Gln27Glu polymorphism is located within the N-
terminal domain as shown in Figure 2.3.  The allelic frequencies of the Gln 27 (55%) and 
Glu 27 (45%) variants are quite similar.  In vitro studies have demonstrated that the Gln  
Glu polymorphism, like the Arg  Gly polymorphism, does not affect ligand binding or 
adenylate cyclase activity [27, 28].  Like the Gly 16 variant, the Glu 27 form appears to 
influence receptor downregulation.  However, studies indicate that the effect of the Glu 27 
variant is opposite to that of the Gly 16 variant.  Research comparing the Gln 27 and Glu 27 
variants of the β2-AR has shown that the Glu 27 form protects against downregulation of β2-
AR expression following exposure to antigen [29, 35].  Clinical studies have demonstrated 
that subjects with the Glu 27 β2-AR variant possess 4 times less reactive airways than those 
with the Gln 27 form [35]. 
 The third, and final, polymorphism of significance is located at amino acid site 164, 
which can be either the threonine (Thr) or isoleucine (Ile).  This polymorphism, unlike the 
Gly 16 and Glu 27 variants, is very rare.  In fact, the allelic frequency of the Thr  Ile 
polymorphism is approximately 1% [48].  As shown in Figure 2.3, the Thr164Ile 
polymorphism is located within the fourth transmembrane domain.  Notably, the Thr  Ile 
polymorphism lies adjacent to the serine (Ser) residue located at site 165.  Because this Ser 
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residue is believed to interact with the hydroxyl group (OH) of β2-AR ligands, the Thr164Ile 
polymorphism is thought to influence ligand binding [35].   Studies comparing the Thr 164 
and Ile 164 variants demonstrated that Ile 164 receptors exhibit a four-fold lower affinity for 
various β2-AR ligands when compared to Thr 164 variants [25].   Additionally, the Thr164Ile 
polymorphism appears to have an effect on adenylate cyclase activation.   Research has 
shown that the Ile 164 variant exhibits a decreased level of basal and ligand-induced 
adenylate cyclase activity [25, 26, 35].  Unfortunately, there is very little data exploring the 
physiological effect of this polymorphism due to the scarcity of the Ile 164 variant within the 
human population [29, 35].  
 It is also important to recognize that though these polymorphisms have received much 
attention, there is a great deal of conflicting data regarding their physiological relevance.  
This inconsistency is believed to be the result of the linkage disequilibrium that exists with 
respect to the β2-AR polymorphisms.  It has become evident these polymorphisms are linked 
and give rise to certain haplotypes.  For instance, subjects that are homozygous for Glu 27 
are almost always homozygous for Gly 16.  Indeed, the Arg16Arg/Glu27Glu haplotype exists 
in nature but makes up less that 1% of the population [29, 72].   Many of the in vitro studies 
investigated only one polymorphism at a time.  As a result, these studies did not account for 
the combined effect of multiple polymorphic loci.  Also, certain haplotypes are more 
commonly associated with specific races [6, 29].  
 As indicated above, the β2-AR polymorphisms are capable of influencing receptor 
activity.  Without a doubt, these polymorphisms affect β2-AR function in vitro.  The in vivo 
effects of the various β2-AR polymorphisms, on the other hand, have been more difficult to 
determine. To date, the majority of the research focusing on the physiological relevance of 
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these SNPs indicates that β2-AR polymorphisms do not alter disease susceptibility and are, 
therefore, not “disease-causing.”   Instead, it is believed that these polymorphisms modify 
disease progression [6].  It is also believed that β2-AR polymorphisms influence receptor 
response to various adrenergic agents.  Understanding the effect of these polymorphic 
variants upon adrenergic therapy is vital to improving current therapeutic techniques.   
Nevertheless, due to the variation associated with β2-AR haplotypes, large populations must 
be studied to fully assess the physiological relevance of these polymorphisms [48].  
 
Inflammatory Role of β 2 – Adrenergic Receptors.  
 Stimulation of ARs via endogenous and exogenous ligands can influence immune 
response.   Over the years, research has indicated that the β2-ARs, in particular, play a major 
role in adrenergic immunomodulation [37, 63, 71].  Importantly, β2-ARs have been identified 
on several immune cell subsets including T cells, B cells, mast cells and macrophages [40, 
54, 56, 63].  As shown in Figure 2.5, stimulation of β2-ARs on these immune cells are 
capable of influencing cellular function and ultimately the immune response.  Historically, 
β2-AR immunomodulation was considered to be anti-inflammatory in nature.  However, most 
of the data exploring the role of β2-ARs in adrenergic immunomodulation has been in vitro 
and in vivo data remains inconclusive [63, 71].  As indicated by the sheer complexity of β2-
AR functionality, it is possible that β2-AR activation has a pleiotropic effect on immune 
response and inflammation.  Figure 2.5 indicates that the immunomodulatory effect of β2-AR 
with regard to macrophage function remains debatable.  Later, in chapters four and five, this 
thesis will explore the dual immunomodulatory property of β2-AR stimulation of 
macrophages.  
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Summary.  
 The adrenergic family of receptors is quite complex and is composed of several 
receptor subsets.  These receptors are ubiquitously expressed and are involved in a variety of 
physiologically relevant functions.  The β2-AR is the most studied member of the adrenergic 
family of receptors.  In fact, the β2-AR is often considered the prototypical adrenoceptor with 
regard to receptor structure.  Studies exploring β2-AR function have demonstrated the diverse 
nature of the receptor.  Signaling and functional responses of the β2-AR vary in response to a 
several factors including cell type, ligand structure, duration of ligand exposure, etc.  In the 
past three decades, increasing amounts of evidence have suggested that β2-ARs play a major 
role in adrenergic modulation of the immune response.  The ultimate outcome of β2-AR 
mediated immunomodulation remains debatable, especially with regard to macrophage 
function.  In later chapters, this thesis will address the discrepancy surrounding the impact of 
β2-AR immunomodulation on the inflammatory response of macrophages. 
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FIGURE 2.1
FIGURE 2.1 – Classification of Adrenergic Receptors. Adrenergic receptors can be 
broadly classified into two major categories – alpha (α) and beta (β) adrenoceptors.  These 
receptor classes can be broken down further into several subtypes as illustrated above [7, 8, 
40, 79]. 
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FIGURE 2.2 – Prototypic Tissue Distribution of Adrenoceptors. Historically, adrenergic 
receptors have been associated with a prototypic tissue distribution.  However, it is well 
known that adrenoceptors are not limited to a certain tissue or cell type and can be found on a 
variety of cells, including cells of the immune system [9, 63, 77, 79] 
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FIGURE 2.3 
FIGURE 2.3 – β 2-Adrenergic Receptor Structure.  The β2-AR is a member of the GPCR 
family of receptors.   As shown above, the β2-AR has seven transmembrane-spanning regions 
that give rise to three intracellular and three extracellular loops.  The N-terminal domain is 
located extracellularly, and the C-terminal is found intracellularly.  The polymorphic sites are 
indicated in black.  The yellow cysteine residues are involved in the formation of disulfide 
bonds, which are important for stabilizing the ligand-binding pocket.  The four amino acid 
residues involved in ligand-binding are indicated in red.   Finally, the amino acid residues 
involved in G-protein coupling are shown in green [23, 37, 63, 77]. 
 
Adapted by permission from Elsevier Ltd: [Journal of Allergy and Clinical Immunology] 
Johnson, M. Molecular mechanisms of β2-adrenergic receptor function, response, and 
regulation. J Allergy Clin Immunol 17:18-24. © 2006. 
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FIGURE  2.4  
FIGURE 2.4 – β 2-Adrenergic Receptor Signaling.  The accepted dogma of β2-AR 
signaling results in the increase of cAMP.  As illustrated above, research has demonstrated 
that signaling can occur via Gs or Gi mechanisms.  The α-subunit of the Gs protein couples 
with adenylate cyclase (A-C).  This leads to the upregulation of cAMP, which results in the 
activation PKA. PKA can go on to activate other signaling molecules leading to changes in 
cellular activity. PKA also phosphorylates the β2-AR and causes the uncoupling of the 
receptor to Gs.  The receptor then couples with the βγ-subunit of the Gi protein. The Gi 
pathway requires an accessory molecule (β-arrestin), which serves as a scaffold for the other 
molecules in the signaling pathway.  It is important to note, that although not shown here, 
research has shown that β2-AR signaling can occur via G-protein independent mechanisms as 
well [37, 40, 68, 79].   
 
Adapted by permission from Elsevier Ltd: [Journal of Allergy and Clinical Immunology] 
Johnson, M. Molecular mechanisms of β2-adrenergic receptor function, response, and 
regulation. J Allergy Clin Immunol 17:18-24. © 2006. 
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FIGURE 2.5  
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FIGURE 2.5 – Immunomodulatory Properties of β 2-Adrenergic Receptor Stimulation of 
Immune Cells.   The β2-AR is commonly associated with its role in airway reactivity.  
However, in recent years, the role of β2-AR with regard to adrenergic immunomodulation has 
gained a great deal of interest.  Many immune cells are known to express β2-ARs.  Moreover, 
research has demonstrated that stimulation of these receptors can alter immune cell function, 
which influences immune response and inflammation [54, 71].   
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CHAPTER III:  MACROPHAGES 
 
 
  
To fully explore the effect of adrenergic modulation on macrophage inflammatory 
immune response, it is imperative to have a basic understanding of cells belonging to the 
mononuclear phagocyte system.   Macrophages and macrophage-like cells are derived from a 
common precursor and are capable of carrying out a variety of cellular functions including 
phagocytosis, antigen presentation and inflammatory mediator production [14, 19].  
Recently, numerous lines of research have focused on determining the effect of β2-AR 
stimulation upon macrophage response.  However, there is some debate over whether β2-AR 
immunomodulation of macrophage function results in a pro- or anti- inflammatory response 
[6, 12, 30, 42].  By providing the background necessary to understand macrophage function, 
the contents of this chapter are designed to enhance comprehension of β2-AR modulation of 
macrophage response during inflammation.  
 
Macrophages and the Immune System. 
 The immune system can be divided into two components based on the degree of 
specificity. These two divisions are known as the innate and adaptive immune systems.   
Though these divisions vary with respect to specificity, both systems are capable of 
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distinguishing between self vs. non-self.   Innate immunity is present at birth and serves as 
the body’s first line of defense against foreign pathogens.  The innate immune response is 
often referred to as “non-specific” immunity as it does not rely on antigen-specificity to 
mount a productive response.  The adaptive immune response, on the other hand, is capable 
of recognizing, responding to and remembering specific pathogens. Unlike adaptive 
immunity, the innate immune response is unable to confer long-term, immunologic memory.   
The innate and adaptive immune systems interact extensively via cell-to-cell contact and 
through various inflammatory mediators.  In fact, many cells and molecular components of 
the innate immune system are also employed by adaptive immunity.  By working together, 
these two divisions provide valuable protection against numerous pathogens [14, 19, 32].   
 Macrophages belong to the mononuclear phagocytic family of immune cells, which 
was formerly known as the reticulo-endothelial system (RES).  The mononuclear phagocytic 
family is made up of peripheral blood monocytes and tissue macrophages in their many 
forms.  These cells share both a common precursor and similar morphology.  As shown in 
Figure 3.1, macrophages arise from pluripotent haematopoietic stem cells located in the bone 
marrow.  These pluripotent precursors further differentiate into monoblasts, monocytes and 
eventually mature to become tissue macrophages [14, 27, 32].  After leaving the bone 
marrow, the first cell of this family to enter peripheral blood is the monocyte.  Upon 
migration into tissues, these monocytes differentiate and mature to become macrophages.  It 
is important to note that this differentiation process involves the presence of an important 
combination of polypeptide growth factors including macrophage colony-stimulating factor 
(M-CSF or CSF-1), granulocyte-macrophage colony-stimulating factor (GM-CSF), 
interleukin-6 (IL-6), interleukin-3 (IL-3), stem cell factor (SCF), interleukin-1 (IL-1) and 
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interferon-γ (IFN-γ) [24, 27, 28, 44].  However, studies indicate that M-CSF is the only 
colony-stimulating factor that is absolutely necessary for macrophage differentiation and 
proliferation in vivo. Furthermore, in vitro experiments have shown that M-CSF alone is 
enough to successfully direct macrophage differentiation from bone marrow progenitors [16, 
17, 32].   
 After settling in various tissues throughout the body, macrophages have the potential 
to become activated.  Activation results in larger cell size, increased production of 
inflammatory mediators and enhanced phagocytic ability [15, 19, 21].   Following activation 
via external stimuli, macrophages can exhibit divergent morphology and function.  For 
instance, a subset of activated macrophages may differentiate into epithelioid cells.  These 
specialized macrophages get their name due to the noticeable increase in cytoplasm and 
similar appearance to squamous epithelial cells.    Additionally, activated macrophages may 
fuse together and form multinucleated giant cells.  These two cell types are the primary 
cellular constituents associated with the formation of granulomas [23, 29].  
Macrophages are ubiquitous and can be found throughout the body.  Those 
macrophages residing in different tissues possess distinctive functional properties and vary in 
their expression of surface molecules [14, 15, 19].  Over time, two major theories have 
developed to explain these variations.  The first theory suggests that different precursors exist 
for each issue type.  Based on the second theory, the microenvironment in which the cell 
resides has a powerful impact upon macrophage differentiation.  Several lines of research 
support the latter theory as macrophage cultures derived from a single stem cell progenitor 
can exhibit heterogeneity based on variation of culture conditions [14, 32].   As shown in 
Figure 3.1, these cells been given explicit names based on their specific location.  For 
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example, macrophages of the CNS are called microglia while those located in the liver are 
called Kupffer cells.   Moreover, macrophages residing in the bone are called osteoclasts, and 
alveolar macrophages are those macrophages found in the lung [14, 19]. 
 
Macrophage Function. 
 Macrophages play a dual role in host defense by contributing to both the innate and 
adaptive immune responses.  Indeed, these cells function not only as important effector cells 
of the innate immunity but also as accessory cells in the adaptive immune response.  
Macrophages are responsible for three major functions.  These functions include 
phagocytosis, antigen presentation and immunomodulation [19, 21].  Macrophages contribute 
to host defense via their participation in the initiation, maintenance and resolution of the 
inflammatory immune response [14, 21, 32].  Furthermore, the functional responses of 
macrophages are quite complex and are tightly regulated under normal circumstances.  If not 
tightly controlled, the inflammatory response of macrophages can contribute to exacerbated 
cellular and tissue damage [19, 32].   
 Macrophages were originally identified based on their phagocytic properties.  As 
phagocytic cells, an important function of macrophages is to ingest cellular debris and 
foreign pathogens.  Once engulfed, the microbicidal activity takes place within intracellular 
vesicles known as phagolysozomes.  These phagolysozomes are formed by the fusion of 
lysozomal vesicles with phagosomes, which contain the ingested materials [14, 19, 21].  To 
physically ingest these pathogens, macrophages must recognize harmful microbes via cell-
surface receptors [14, 19, 33, 39].  Importantly, these receptors are capable of discriminating 
between the surface molecules of the host and those of foreign pathogens.   These receptors 
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include mannose receptors, scavenger receptors, receptors for opsonins and toll-like receptors 
(TLRs).  Ligation of these receptors results in a variety of outcomes including macrophage 
activation, phagocytosis and the production of various inflammatory mediators [1, 2, 21].   
For instance, TLR activation can lead to the upregulation and secretion of various 
inflammatory mediators, which help direct both the innate and adaptive immune responses.  
To date, eleven TLRs have been identified [2, 9, 10, 41].  Due to limited space, a detailed 
discussion of each TLR and their functional responses cannot be addressed.   For the purpose 
of this thesis, TLR 4 activation will be discussed in more detail later in this chapter.  
 Antigen presentation is another important function of macrophage activity.  In fact, 
macrophages, along with dendritic cells (DCs) and B cells, are often referred to as 
professional antigen presenting cells (APCs). With regard to the adaptive immune system, 
antigen presentation is often considered the most important function of the macrophage [14, 
26].  Following phagocytosis, ingested pathogens are degraded enzymatically within 
intracellular vesicles to generate antigenic peptides.  Some of these peptides possess 
structural properties that allow them to adhere to the peptide-binding clefts of the major 
histocompatibility complex (MHC) class II molecule [14, 19, 32].  As a result, these peptides 
are presented in the context of MHC II on the macrophage cell surface.  The peptide-MHC II 
complex is presented to the T cell receptor (TCR) of CD4+ T lymphocytes.  Then, the CD4+ 
effector T cells and the macrophages engage in a beneficial “cross-talk” that is critical to the 
development of a productive immune response against intracellular pathogens [14, 19, 26].  
 The immunomodulatory character of macrophages is yet another valuable function of 
these multi-purpose cells.  This role is perhaps the most important function with regard to β2-
AR modulation of macrophage response.  It is well known that activated macrophages 
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secrete various cytokines capable of modulating the immune response [14, 19, 21, 26].   
Additionally, activated macrophages are known to release other inflammatory mediators 
including various chemoattractants and short-lived lipid mediators such as prostaglandins and 
leukotrienes [14, 32].   It is also known that activated macrophages are capable of releasing 
reactive oxygen species into the extracellular space, which not only influence inflammatory 
response but also led to tissue destruction [7, 18].  Together, these inflammatory molecules 
represent another functional bridge between the innate and adaptive immune systems [21, 
32].  
 
Macrophage Activation. 
 For years, it has been accepted that macrophage function greatly influences the 
quality, duration and extent of inflammatory reactions.  In order to exert these effects, the 
macrophage must undergo conversion from a resting state to one of activation.   The term 
“activated macrophage” refers to a macrophage that has enhanced phagocytic, antigen 
presentation and immunomodulatory capabilities.  It is important to note that, following entry 
into peripheral tissues, the majority of monocyte/macrophage cells die via apoptosis.  Those 
cells that survive can differentiate and become activated with or without the need of a 
priming event.  Stimuli for activation include T cell-derived cytokines, microbial products, 
immune complexes and various chemical mediators [14, 19, 21].  Activated macrophages 
have an altered phenotype and cellular morphology.  They appear larger, possess more 
pseudopods and exhibit increased ruffling of the plasma membrane [14, 19].  As illustrated in 
Figure 3.2, the process of macrophage activation is quite complex and cannot be covered in 
great detail within the scope of this thesis [15].  Since many of the studies exploring β2-AR 
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immunomodulation were done in conjunction with lipopolysaccharide (LPS)-costimulation, 
LPS-induced macrophage activation will be discussed in greater detail in the following 
section.  
 
LPS Activation of Macrophages. 
 Bacterial LPS is a major constituent of the outer wall of Gram-negative bacteria and 
is known to be a potent activator of macrophages.  More specifically, lipid A, a substructural 
component of LPS, is responsible for mediating macrophage activation [8, 25, 35].  Upon 
activation by LPS, a variety of inflammatory mediators are expressed in macrophages 
following the upregulation of various transcription factors including nuclear factor κB (NF- 
κB) and activator protein – 1 (AP-1).  These signaling pathways are very complex and will 
be summarized below and in Figure 3.3 [22].  
The LPS receptor complex is comprised of CD14, TLR 4 and the myeloid 
differentiation protein -2 (MD-2) [1, 13]. The LPS-TLR 4 signaling pathway arises from 
cytoplasmic Toll/IL-1 receptor (TIR) domains of the TLR 4 receptor.  These TIR domains 
interact with a TIR domain-containing adaptor protein known as MyD88.   While MyD88 
has a C-terminal TIR domain that promotes its association with TLR 4, it also has an N-
terminal death domain.  The MyD88 death domains serve to recruit serine/threonine kinases 
such as IL-1 receptor-associated kinases (IRAK) to the cell membrane.  The IRAK 1/ IRAK 
4 molecules associate with the receptor complex transiently.  IRAK 1 dissociates from the 
receptor complex following phosphorylation by IRAK 4.  At this point, IRAK is free to 
associate with and activate TNF-receptor-associated factor 6 (TRAF 6).   TRAF 6 goes on to 
initiate two distinct signaling pathways by activating the IkappaB kinase (IKK) complex and 
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the MAPK signaling pathway.  Activation of the IKK complex leads to the phosphorylation 
of IκB.  Once phophorylated, IκB is degraded and NF-κB is liberated, which results in the 
transcription of numerous inflammatory cytokines.  TRAF 6 activation of the MAPK 
pathway leads to the activation of the AP-1 transcription factor.  Like NF-κB, activation of 
AP-1 leads to the transcription of a variety of inflammatory cytokines [1, 25, 26, 41].   
Originally, TLR signaling was believed to be entirely MyD88-dependent. In recent 
years, however, research has demonstrated a MyD88-independent pathway in both TLR 3 
and TLR 4 signaling pathways. As shown in Figure 3.3, LPS-mediated signaling through 
TLR 4 can lead to the activation of NF-κB and the phosphorylation of IRF 3 via a MyD88 
independent pathway.  This MyD88-independent signaling pathway leads to the upregulation 
of Type I interferons such as IFN-β.   IFN-β goes on to activate signal transducers and 
activator of transcription 1 (STAT 1), which leads to induction of several IFN-inducible 
genes [13, 14, 19, 22, 25].    
 
Activated Macrophages, Inflammation and β2-Adrenergic Immunomodulation.  
 As mentioned earlier, activated macrophages undergo changes that enhance their 
microbicidal effectiveness and their ability to modulate the inflammatory immune response.  
These changes include enhanced phagocytic ability, microbial killing, antigen presentation 
and inflammatory mediator production. It is widely accepted that activated macrophages 
secrete pro-inflammatory cytokines including TNF-α, IL-1β and IL-6 [14, 15, 19].  Activated 
macrophages also release nitric oxide (NO), which is produced by inducible nitric oxide 
synthase (iNOS) [14, 19].  Furthermore, macrophage activation leads to enhanced respiratory 
burst activity.  The macrophage respiratory burst is characterized by the release of various 
 60 
reactive oxygen species (ROS) including superoxide radicals and hydrogen peroxide [14, 18, 
19]. Together, these chemical mediators function to recruit and activate a variety of immune 
cells, including other macrophages, at the site of inflammation.  As a result, these 
inflammatory molecules are highly effective mediators of the inflammatory response.  If left 
unchecked, however, these inflammatory mediators, which are typically beneficial to the 
host, can exacerbate inflammation and lead to tissue and organ damage.   
  Due to their role in the inflammatory process, several lines of research have focused 
on exploring various ways to modulate macrophage activity. Based on the 
immunomodulatory potential of β2-ARs, several investigators have turned their attention 
toward determining the effect of β2-AR stimulation upon macrophage response [5, 34, 40, 
42, 43].   Peripheral blood monocytes are known to express high levels of surface β2-ARs.  
Though tissue macrophages express β2-ARs, research has shown that they possess fewer β2-
ARs than monocytes [3, 20, 37].  These receptors are known to interact with endogenous 
catecholamines and exogenously administered adrenergic drugs.  Since macrophages express 
fewer β2-ARs, they exhibit reduced sensitivity to adrenergic agonist compared to monocytes 
[20].  Although the major sources of  these catecholamines are chromaffin cells of the 
adrenal medulla and noradrenergic neurons, reports have indicated that macrophages release 
epinephrine and norepinephrine following stimulation with LPS or IFN-γ.  However, the 
source of these macrophage-associated catecholamines is unclear.  While some studies 
suggest that macrophages acquire epinephrine and norepinephrine from extracellular fluids, 
others indicate that macrophages actually synthesize these catecholamines.   Currently, the 
consensus is that both uptake and synthesis are responsible for the presence of epinephrine 
and norepinephrine in macrophages [4, 11].  The novelty of these macrophage-derived 
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catecholamines lies within their ability to modulate macrophage immune response in an 
autocrine fashion [11, 38].  
 Over time, numerous reports have accumulated demonstrating the 
immunomodulatory effect of β2-AR stimulation upon macrophage response.  Research has 
shown that activation of β2-ARs can influence a variety of macrophage functions including 
chemotaxis, expression of adherence molecules and inflammatory mediator production [31, 
36].  For the purpose of this thesis, β2-AR-mediated regulation of inflammatory mediator 
production by monocytes and macrophages is of chief interest. Stimulation of β2-ARs on 
macrophages has been traditionally considered to have an anti-inflammatory effect upon 
inflammatory mediator release.  However, recent reports suggest that β2-AR may actually 
promote a pro-inflammatory response by macrophages [40, 42].  Indeed, as shown in Figure 
2.5, studies investigating the effect of β2-AR activation upon production of inflammatory 
cytokines by macrophages are inconclusive [40].  Understandably, this dual modulatory 
property of β2-ARs with respect to macrophage activity is controversial and will be discussed 
in greater detail in the following chapters. 
 
Summary.  
 Macrophages belong to the mononuclear phagocyte system.  This system is defined 
as a family of cells including bone marrow progenitors, peripheral blood monocytes and 
tissue macrophages in their various forms.  Macrophage development is complex and is 
composed of several phases for which there are distinct cell phenotypes.  Briefly, 
macrophages are derived from a common precursor in the bone marrow, which differentiates 
to form blood monocytes.  When monocytes exit the blood to enter peripheral tissues, these 
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cells differentiate further to become macrophages [14, 26, 32].   Once residing within tissues 
throughout the body, macrophages can become activated via a variety of mechanisms (Figure 
3.2).  Macrophages are much more than the “big eaters” that their name implies.  Indeed, 
these cells are important inflammatory cells, which participate in both the innate and adaptive 
immune responses [14, 19].   Though phagocytosis of foreign material is a major function of 
the macrophage, these cells also function as professional APCs and potent 
immunomodulators of the inflammatory response [14, 19].  Because of the controversial role 
of β2-ARs in modulating the inflammatory response of macrophages, the immunomodulatory 
potential of macrophages is of critical importance with regard to this thesis. 
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FIGURE  3.1 
 
 
 
 
 FIGURE 3.1 – Macrophage  Development and Maturation.  Macrophages are derived 
from pluripotent haematopoietic stem cells that reside in the bone marrow.  While in the bone 
marrow, these cells differentiate into monoblasts and promonocytes. The first cell of this 
family to appear in peripheral blood is known as a monocyte.  As these monocytes leave the 
blood and enter various tissues and organs the body, they become macrophages.   Once 
distributed throughout the body, macrophages differentiate even further and are capable of 
becoming activated.  Importantly,  macrophages located in different organs of the body 
receive special names.  For instance, macrophages of the CNS are known as microglia.  Those  
found throughout the airways and the lung are known as alveolar macrophages.  Kupffer cells 
are macrophages of the liver, and osteoclasts are located in bone [13, 19, 21, 26, 27]. 
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FIGURE 3.2 
 
 
 
 
 
 
 
FIGURE 3.2 – Macrophage Activation.  Macrophage activation is a complex process.  
Activating stimuli include T-cell derived cytokines, microbial products, immune complexes 
and various chemical mediators.   Importantly, activated macrophages have enhanced 
phagocytic, antigen presentation and immunomodulatory capabilities [13-15, 19, 21]. 
 
Adapted by permission from Macmillan Publishers Ltd: [Nature Reviews Immunology] 
Gordon, S. Alternative activation of macrophages. Nat Rev Immunol 3:23-35. © 2003. 
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FIGURE 3.3 – LPS Activation via TLR 4 Stimulation.  The LPS receptor complex is made 
up of CD14, TLR 4 and MD-2.  As shown above, upon stimulation, TLR 4 initiates the 
intracellular signaling cascade via the recruitment of MyD88 and IRAK 1/ IRAK 4 to the 
membrane.  IRAK 1/ IRAK 4 associates with the receptor complex transiently.  Once 
phosphorylated, IRAK 1 dissociates from MyD88 and the receptor complex.  At this point, 
IRAK activates TRAF 6.  TRAF 6 then goes on to activate two signaling pathways via 
activation of IKK complex and the MAPK signaling pathway.  Activation of the IKK 
complex leads to the degradation of IκB and liberation of NF-κB.  Activation of the MAPK 
signaling pathway ultimately leads to the activation of the AP-1 transcription factor. 
Activation of both NF-κB and AP-1 lead to the transcription of inflammatory cytokines.   It is 
important to note that there is also a MyD88-independent pathway that leads to IRF 3 
activation and upregulation of  Type 1 Interferons such as IFN-β [9, 19, 22, 26].     
 
Adapted by permission from Macmillan Publishers Ltd: [CELL DEATH AND 
DIFFERENTIATION] Kawai, T., and S. Akira. TLR signaling. Cell Death Differ 13:816-825 
© 2006.  
 
FIGURE 3.3 
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CHAPTER IV:  ANTI-INFLAMMATORY MODULATION OF MACROPHAGE 
RESPONSE BY β2-ADRENERGIC RECEPTOR ACTIVITY 
 
 
 
 As multi-functional cells of the immune system, monocytes and macrophages play an 
instrumental role in modulating the inflammatory immune response.  Because of this role, 
regulating macrophage activity can drastically alter the course of many inflammatory 
processes.  In recent years, the ability of adrenergic drugs to modulate cells of the immune 
system, especially monocytes and macrophages, has gained interest.  Accepted dogma 
indicates that β2-AR stimulation has an anti-inflammatory effect upon monocyte and 
macrophage responses.  To date, studies exploring the anti-inflammatory effect of β2-AR 
activation have focused extensively on the production of numerous inflammatory mediators 
including cytokines, chemokines, NO and superoxide anions.  The contents of this chapter 
are designed to provide a comprehensive review of existing literature with regard to the anti-
inflammatory effects of β2-AR modulation upon cells of the mononuclear phagocytic system. 
 
β2-Adrenergic Receptor Anti-inflammatory Modulation of Cytokine Production. 
 Cytokines are small, secreted proteins involved in mediating inflammation.   Acting 
as signaling compounds, cytokines promote cell-to-cell communication during the 
inflammatory immune response [49, 72].  Activated macrophages produce a number of pro- 
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and anti-inflammatory cytokines including tumor necrosis factor-α (TNF-α), IL-1β, IL-6 and 
interleukin-10 (IL-10) [29, 31].  Research indicates that elevated cAMP levels are associated 
with reduced cytokine production [7, 53, 88].  Since β2-AR activation is known to increase 
cAMP levels, several investigators have focused on determining the value of β2-AR agonists 
as modulators of cytokine production.  These studies have been conducted using both in vitro 
and in vivo model systems [22, 26, 34, 35, 37, 40, 42, 44, 46, 47, 66, 78, 85, 92, 94].  
However, in vivo studies are often unable to isolate the effects of β2-ARs on monocyte and 
macrophage function.  This is due to the fact that monocytes and macrophages are not the 
only cells capable of producing cytokines in vivo.  Indeed, cytokines, and other inflammatory 
mediators, are produced by a variety of cell types including (but not limited to) fibroblasts, 
endothelial cells, lymphocytes, and smooth muscle cells [49, 72].  As a result, much of the 
work done to explore the effects of β2-AR stimulation upon monocyte/macrophage-mediated 
cytokine production has been conducted in vitro. Historically, research has demonstrated that 
β2-AR stimulation of monocytes and macrophages downregulates pro-inflammatory cytokine 
production and potentiates the release of anti-inflammatory cytokines. 
 
TNF-α: 
TNF-α is a pleiotropic inflammatory cytokine produced primarily by monocytes and 
macrophages.  This cytokine is involved in a wide array of biological processes including 
cellular proliferation, differentiation, apoptosis, lipid metabolism, coagulation and 
endothelial function [49, 72, 98].  Following LPS-activation of macrophages, TNF-α is the 
first cytokine to appear in a cascade of several inflammatory cytokines [28, 49].  In models of 
systemic inflammation induced by bacteria and/or bacterial by-products, the earliest cytokine 
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to emerge into circulation is TNF-α.  Furthermore, animal studies have shown that 
neutralization of TNF-α activity during sepsis is important in protecting against lethality [28, 
39, 41, 90].  Based on this knowledge, inhibition of TNF-α activity has become a major 
target of therapeutic exploration.  Over the past two decades, several lines of research have 
focused on exploring the impact of β2-AR agonists upon TNF-α production by LPS-treated 
monocytes and macrophages. 
In 1992, Severn et. al. published one of the earliest papers addressing the anti-
inflammatory potential of β2-ARs with regard to monocyte production of TNF-α.  These 
experiments were conducted in vitro using human whole blood and the THP-1 human 
monocytic cell line.  Results demonstrated a dose-dependent reduction in LPS-induced TNF-
α production following exposure to epinephrine.  Treatment with isoproterenol, a β-AR 
specific agonist, had similar effects upon TNF-α levels.  Moreover, the use of a β-AR 
antagonist prevented the effects of epinephrine/isoproterenol on TNF-α production.  Use of 
an α-AR antagonist, on the other hand, had no effect.  This paper also reported increased 
cAMP levels following β-AR activation in LPS-treated cells.  As mentioned earlier, 
increased cAMP levels are believed to reduce the production of various cytokines, including 
TNF-α.   Experiments designed to explore the mechanism of β-AR regulation indicated that 
LPS-induced TNF-α mRNA levels were not affected by exposure to 
epinephrine/isoproterenol.  This, along with time-course data, prompted Severn and 
colleagues to suggest that β-AR mediation of TNF-α production occurs at the post-
transcriptional level.  Importantly, inhibition of TNF-α was only observed if 
epinephrine/isoproterenol was administered at the same time of LPS co-stimulation.  A 24-
hour (h) pretreatment with epinephrine/isoproterenol actually led to increased TNF-α 
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production following LPS exposure.  This pro-inflammatory caveat was attributed to 
decreased cAMP levels (below basal levels) and receptor desensitization [78].  Though the 
report by Severn et. al. revealed that β-AR stimulation (and not α-ARs) influences TNF-α 
production by macrophages, the β-AR subtype was not directly identified by this paper.  The 
general consensus supports the belief that β2-ARs mediate the catecholamine-induced 
decrease in TNF-α production [35, 47, 64, 66, 77].  However, several papers have implicated 
β1-ARs in this process.  It is important to note that most of these studies used norepinephrine 
as the β-AR ligand.  Since norepinephrine is known to preferentially bind α2- and β1-ARs, 
ligand-specificity could contribute to these claims [42, 94, 95].   
Following these early reports, several papers were published that confirmed the 
involvement of β2-ARs in modulating LPS-induced TNF-α production by numerous cells of 
the monocytic lineage.  These studies employed various monocyte/macrophage cell lines, 
human peripheral blood monocytes (PBMCs), microglia, alveolar macrophages, renal 
macrophages and Kupffer cells [4, 8, 25, 34, 35, 37, 40, 42, 44, 77, 101].  Many of these 
publications contradicted the idea put forth by Severn et. al. that β-AR modulation of 
cytokine production did not work at the level of transcription [4, 40, 44, 66, 67, 86].  For 
instance, a paper by Hetier and colleagues indicates that β2-AR activity inhibits both the 
transcription and release of TNF-α  by LPS-treated murine microglial cells [40].  In addition 
to the in vitro studies, numerous experiments were conducted using in vivo model systems 
[22, 59, 77, 84, 87].  Although TNF-α levels were lowered following exposure to β2-AR 
agonists in many of these experiments, it is difficult to attribute the in vivo inhibitory effects 
of β2-AR stimulation directly to monocyte and/or macrophage activity.  
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Though much of the work regarding this topic used exogenously administered 
catecholamines and/or β2-AR drugs, several publications have explored the effect of 
macrophage-derived catecholamines upon inflammatory mediator production [23, 81].  As 
discussed in chapter three, macrophages are known to possess intracellular stores of 
epinephrine and norepinephrine [10, 81].  Based on this knowledge, a 1994 study by 
Spengler and colleagues investigated the effects of macrophage-derived norepinephrine upon 
TNF-α production.  Results from this study demonstrated that macrophage-derived 
catecholamines are capable of regulating TNF-α production in an autocrine manner [44, 81].  
While this phenomenon was attributed to β-AR activity, the particular subtype responsible 
for these results has yet to be defined. 
In addition to exploring β2-AR modulation of TNF-α production, Lowry et. al. 
investigated the effect of β2-AR stimulation upon TNF-α receptor (TNFR) expression. 
Existing data suggests TNFR expression is linked to TNF-dependent apoptosis.  As a result, 
it is believed that TNFR expression plays an important role in mediating inflammatory cell 
turnover [96].  It is well established that TNFR expression is lost during both experimental 
and clinical endotoxemia [12, 21, 91].  In septic patients, the loss of TNFR activity is 
associated with poor outcome.  The re-establishment of these receptors, on the other hand, is 
associated with increased survival [12].  Importantly, agents that increase cAMP levels 
increase TNFR expression [12, 35, 92].  Since β2-AR stimulation leads to the upregulation of 
cAMP, Lowry and colleagues published a set of papers exploring the effect catecholamines 
upon TNFR surface expression of LPS-treated monocytes.  Results from these studies 
demonstrate that epinephrine prevents LPS-induced downregulation of TNFR expression on 
human monocytes.  The use of AR-specific antagonists demonstrated that this effect was 
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primarily mediated through the activation of β2-ARs [35, 92].  These studies, in conjunction 
with earlier studies, indicate that β2-AR activity influences the bioavailability of TNF-α not 
only through TNF-α production but also through TNFR expression. 
 
IL – 1β: 
 Like TNF-α, IL-1β is a potent inflammatory cytokine produced by monocytes and 
tissue macrophages in their various forms.  IL-1β is initially translated as a pro-peptide.  This 
immature form of IL-1β (pro-IL-1β) is the predominate intracellular form of the protein.  
Processing of pro-IL-1β to the mature form requires a cysteine-dependent protease known as 
IL-1β-converting enzyme (ICE) [3, 5, 61].  It is important to note that the release of IL-1β is 
often incomplete, even in macrophages.  This results in the presence of both extracellular and 
cytoplasmic IL-1β [72].  The mature form of IL-1β is believed to play a key role in the 
inflammatory immune response and is involved in a multitude of biological activities [49, 
72].  Based on what is known about β2-AR modulation of TNF-α production, several lines of 
research have focused on identifying the effect of adrenergic modulation, if any, on IL-1β 
production by LPS-treated monocytes and macrophages.  
 In 1986, a paper published by Koff et. al. introduced the idea of catecholamine-
induced modulation of IL-1 production by macrophages.  This study demonstrated the ability 
of epinephrine and norepinephrine to inhibit LPS- or IFN-γ-induced IL-1 production by 
murine peritoneal macrophages.  Analysis of intracellular and extracellular levels of IL-1 
indicated that catecholamines are capable of blocking IL-1 synthesis without affecting IL-1 
release. This was demonstrated by the fact that exposure to norepinephrine or epinephrine 
resulted in proportional decreases of both intracellular and extracellular concentrations of IL-
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1.  Although there was no data in this paper to prove the actual mechanism of action, Koff 
and colleagues hypothesized the decrease in IL-1 production was mediated by increased 
cAMP levels [55].   The paper by Koff and colleagues also failed to directly address the 
receptor subtype responsible for the observed effects.  Fortunately, several papers followed 
aimed at identifying the subtype involved in modulating IL-1β production by 
monocytes/macrophages.  According to current literature, the inhibitory effects of 
catecholamines and adrenergic drugs on IL-1β production by LPS-treated monocytes and 
macrophages are primarily mediated via β2-AR activity [23, 40, 101, 102].  Furthermore, 
numerous lines of research have confirmed these early observations using a variety of cell 
types belonging to the mononuclear phagocytic system [4, 8, 23, 40, 102].   Notably, like 
TNF-α, existing data indicates that macrophage-derived catecholamines are capable of 
modulating IL-1β production in an autocrine fashion [10, 23, 81].  Although the impact of β2-
AR modulation varies based on cell type, this collection of papers indicates that adrenergic 
modulation is a relevant mechanism for regulating LPS-induced IL-1β production by 
monocytes/macrophages. 
  
IL-6:  
 IL-6 is an important inflammatory mediator produced by a variety of cell types 
including monocytes and macrophages.  IL-6 carries out a broad spectrum of biological 
activities, many of which overlap those of IL-1β and TNF-α.  All three of these cytokines are 
deemed pro-inflammatory and are valuable players in the “acute-phase response.”  Occurring 
early during infection, the “acute-phase response” refers to the body’s global response to 
foreign pathogens.  Aside from inducing the release of various acute-phase proteins, IL-6 is 
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highly involved in mediating fever [49, 72].  Like TNF-α and IL-1β, the pro-inflammatory 
role of IL-6 has influenced many investigators to explore potential mechanisms of regulating 
IL-6 production including adrenergic immunomodulation.  
 In 1999, Izeboud and colleagues published a paper exploring the effects of the β-AR 
agonist, clenbuterol, upon pro-inflammatory cytokine production by LPS-induced monocytes 
and macrophages.  Data from in vitro studies demonstrate a concentration-dependent 
inhibitory effect of β-AR agonists upon LPS-induced IL-6 production by macrophages.  
Izeboud also extended these experiments to include an in vivo endotoxemic rat model.  In this 
model, plasma levels of IL-6 were lower in experimental groups (β-AR agonist) than in 
control groups (no β-AR agonist) [47].   This data supports the anti-inflammatory effect of β-
AR agonists on IL-6 production.  However, it is impossible to conclude these effects are due 
to β-AR agonist inhibition of macrophage function alone [47].  Because clenbuterol is not a 
β2-AR-specific agonist, the receptor subtype mediating these effects is not fully addressed in 
this set of data.  An additional paper published in 1999 by Izeboud and colleagues directly 
addresses this issue of β-AR subtype specificity.  These studies used β1- and β2-specific 
antagonists to determine which β-AR subtype is responsible for the observed effects.  Results 
from this set of experiments indicate that β2-ARs, and not β1-ARs, are involved in the 
adrenergic immunomodulation of IL-6 production by LPS-stimulated macrophages [46, 47].  
Like with TNF-α and IL-1β, experiments exploring IL-6 activity were extended to include a 
variety of cell types belonging to the mononuclear family of phagocytes [47, 66, 84].   
Over time, a select subset of papers has suggested molecular mechanisms to explain 
the effects of β2-ARs on IL-6 production.  In 1999, Nakamura and colleagues reported that 
the β-AR agonist, isoproterenol, is capable of altering LPS-induced IL-6 gene transcription 
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by monocytes and macrophages.  However, this effect was not dose dependent and was only 
observed at high concentrations (10-5M) of β-AR agonist.  Again, β2-AR-induced increases in 
cAMP levels were cited as a potential factor in regulating IL-6 production [47, 67].   
Unfortunately, the exact signaling mechanisms (second messengers, transcription factors, 
etc) responsible for the β2-AR-mediated reduction in IL-6 transcription were not addressed 
by these studies.  Although there is substantial documentation of the anti-inflammatory effect 
of β2-AR stimulation upon IL-6 production, several publications indicate that β2-AR 
activating agents may actually increase IL-6 production by macrophages.  These pro-
inflammatory effects of β2-AR stimulation will be described in more detail in chapter five.  
 
IL-10: 
 IL-10 is a pluripotent cytokine produced by several cell populations including those 
belonging to the mononuclear phagocytic system.  Unlike TNF-α, IL-1β and IL-6, IL-10 is 
classified as an anti-inflammatory cytokine.  Due to the potent anti-inflammatory properties 
of IL-10, its main biological purpose appears to be the limitation and/or termination of the 
inflammatory immune response.  With regard to macrophage activity, IL-10 functions to 
inhibit the production of pro-inflammatory cytokines [49, 72].  In fact, IL-10 was originally 
called cytokine synthesis inhibiting factor (CSIF) because of its ability to modulate cytokine 
production [72].  Recently, the potent anti-inflammatory activities of IL-10 have prompted 
numerous studies designed to understand and manipulate IL-10 production.  Based on the 
ability of β2-ARs to influence the production of other cytokines, several investigators have 
investigated the effect of β2-AR stimulation on IL-10 production by monocytes/macrophages.  
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 One of the earliest publications addressing β2-AR modulation of IL-10 production 
was published by Suberville et. al. in 1996.  In this paper, the experimental group consists of 
LPS-activated peritoneal macrophages, which were treated with the β-AR agonist, 
isoproterenol.  According to data from these studies, β-AR agonist treatment significantly 
increased IL-10 production by macrophages in the experimental group.  This increase in IL-
10 production occurred in a dose-dependent manner with respect to isoproterenol 
concentration.  Data revealed that the increase in IL-10 release was accompanied by an 
increase in cAMP and IL-10 mRNA levels in isoproterenol-treated groups.  Furthermore, 
treatment with oxprenolol, a β-AR antagonist, inhibited the effects of isoproterenol on IL-10 
production [83].  This paper also proposed the idea that β-AR-induced increases in IL-10 
production may contribute to the well-documented catecholamine-induced reduction in TNF-
α and IL-1β production [35, 55, 64, 83, 93].  However, several papers have provided data to 
contradict this theory [19, 64].  For instance, in 2005, Muthu and colleagues published a 
paper aimed at exploring the link between β2-AR-induced IL-10 and TNF-α production.  
Results from these studies indicate that β2-AR modulation of IL-10 and TNF-α are 
independent of one another.  Indeed, experiments using anti-IL-10 antibodies (Ab) were not 
capable of blocking epinephrine-induced TNF-α production by LPS-stimulated macrophages 
[64].   
Like with other cytokines, many of the original publications did not fully address the 
receptor subtype responsible for β-AR-induced increases in IL-10 production.  Over time, 
publications have emerged suggesting these effects are mediated via the β2-AR subtype [46, 
64].  Furthermore, although there has been mention of cAMP involvement, the signaling 
pathways mediating the effects of β2-AR activity have yet to be elucidated [82].  It is 
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important to recognize that though several papers have provided data supporting the β2-AR-
induced increase in IL-10 production by LPS-treated macrophages, there are several papers 
that indicate that stimulation of β2-ARs has no effect upon IL-10 production.   
 
β2-Adrenergic Receptor Anti-inflammatory Modulation of MIP-1α Production. 
 Macrophage Inhibitory Protein-1α (MIP-1α) is a potent inflammatory mediator 
produced by monocytes and macrophages.  As a member of the CC family of chemokines, 
MIP-1α is chemotactic for mononuclear phagocytes and lymphocytes [49].  Aside from its 
chemotactic properties, MIP-1α is also known to promote macrophage production of TNF-α, 
IL-1 and IL-6 [24, 38].  Furthermore, MIP-1α has been implicated as a contributing agent in 
the pathogenesis of a variety of inflammatory conditions including rheumatoid arthritis, 
asthma and glomerulonephritis [38, 54, 68, 82].  Over the years, due to the pro-inflammatory 
properties of MIP-1α, interest in modulating macrophage production of this multi-purpose 
mediator has increased.  Importantly, with respect to this thesis, several investigators have 
considered adrenergic immunomodulation as a promising mechanism for regulating MIP-1α 
production by monocytes and macrophages. 
 The first paper to explore catecholamine-induced modulation of MIP-1α production 
was published in 1998 by Haskο and colleagues.  In this landmark publication, the authors 
examine the effect of epinephrine and norepinephrine upon MIP-1α production by LPS-
treated macrophages.  This paper employed both the RAW 264.7 murine macrophage cell 
and thioglycollate-elicited murine peritoneal macrophages for experimentation.  Results 
indicate that both epinephrine and norepinephrine inhibit MIP-1α production from LPS-
induced macrophages in a dose-dependent manner.  Use of β-AR antagonists inhibited the 
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anti-inflammatory effects of both epinephrine and norepinephrine. Additional experiments 
employing isoproterenol, a β-AR agonist, mimicked the effects of epinephrine and 
norepinephrine upon MIP-1α production.  The use of an α-AR specific agonist, however, 
had no effect.  Studies employing Northern blot analysis demonstrate that LPS-treated 
macrophages exposed to β-AR activating agents possess lower levels of MIP-1α mRNA than 
macrophages belonging to the control group (no β-AR treatment).  This publication also 
explored the in vivo effects of β-AR stimulation upon MIP-1α production.  In these 
experiments, Hasko et. al. observed lower MIP-1α plasma levels in endotoxemic mice 
exposed to β-AR agonists than in control mice (no β-AR agonist) [38].  In 2003, a paper by 
Li et. al. was published extending these studies to see if β-AR stimulation had the same effect 
upon MIP-1α production in human monocyte/macrophages.  To do this, Li and colleagues 
exposed LPS-stimulated human monocytic THP-1 cells and human PBMCs to epinephrine 
(or isoproterenol) and measured MIP-1α production.  Data from this publication 
demonstrates that epinephrine inhibits MIP-1α production by LPS-treated samples in a dose-
dependent manner.  This reduction in MIP-1α production occurred at both the protein and 
mRNA levels.  While use of α-AR antagonists had no effect upon MIP-1α levels, β-AR-
specific antagonists reversed the effects of epinephrine and β-AR agonists upon MIP-1α 
production [57]. In both papers, β-ARs were implicated in inhibiting MIP-1α production by 
LPS-stimulated macrophages and monocyte [38, 57].  However, neither publication 
determined which adrenoceptor subtype is responsible for the observed effects.   As a result, 
additional studies are required to fully associate β2-AR activity with catecholamine-induced 
inhibition of MIP-1α  production. 
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β2-Adrenergic Receptor Anti-inflammatory Modulation of Nitric Oxide Production. 
 Nitric Oxide (NO) is a multi-purpose molecule produced by many cells of the body 
including monocytes and macrophages.  Aside from its role in regulating vessel tone, NO 
also plays an important role in mediating inflammation.  NO functions not only as a valuable 
inflammatory signaling molecule but also as a fundamental microbicidal agent.  As an 
inflammatory mediator, this molecule is implicated in the pathogenesis of sepsis, psoriasis, 
arthritis, type I diabetes and ulcerative colitis [16, 27, 43, 60, 73].  NO is synthesized from 
the oxidation of L-arginine by NOS.  Currently, there are three known mammalian forms of 
this enzyme.  Endothelial and neuronal NOS are constitutively expressed and are modulated 
by intracellular calcium levels.  Inducible NOS (iNOS), which is found in macrophages, is 
not regulated by increases in intracellular calcium levels.  Instead, iNOS expression is 
induced via interaction with various external stimuli (LPS, TNF-α, IL-1β, etc.).  Once 
induced, iNOS is regulated by the inflammatory milieu present within the microenvironment 
[16, 58].  Moreover, several papers have demonstrated that increases in cAMP levels can 
inhibit iNOS induction [37, 58, 63, 69].  This idea is quite controversial as others have shown 
that increases in cAMP levels increase NO production [62].  Nevertheless, the possibility 
remains that β2-AR stimulation may lead to a cAMP-mediated reduction in iNOS expression.  
Early on, Szabo et. al. reported on the ability of isoproterenol, a β-AR agonist, to 
reduce plasma nitrite levels in LPS-challenged mice.  Unfortunately, due to the numerous 
sources of NO in vivo, adrenergic modulation of macrophage activity may not be responsible 
for these results [84].   In 1999, Sigola and colleagues published a paper designed to explore 
the direct effects of β-AR agonists upon NO production by macrophages.  Using an in vitro 
model system, this set of experiments investigated β-AR-mediated regulation of LPS-
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induced NO production by primary murine peritoneal macrophages.  Upon release from 
activated macrophages, NO rapidly reacts with oxygen to produce nitrite.  As a result, this 
paper (and many others) used the Griess assay to measure nitrite levels as an indication of 
NO production.  Data from these experiments demonstrate that epinephrine treatment results 
in a dose-dependent reduction of nitrate levels in the experimental group.   These results 
could be blocked using β-AR antagonists, which indicates this phenomenon is mediated by 
β-AR activity.   
Although very few studies were done to address the mechanism responsible for the 
observed reduction in NO, Sigola et. al. theorized about the involvement of cAMP and NF-
κB in mediating the inhibitory effects of epinephrine [80].  Throughout time, there have been 
several reports supporting the involvement of cAMP and NF-kB in mediating β-AR-induced 
reduction of NO production [6, 37].  However, more research is required to confirm these 
reports and establish this as an accepted mechanism of action.  In 2001, a paper by Zinyama 
and colleagues presented another mechanism to explain the β-AR-induced attenuation of NO 
production by macrophages. In this mechanism, the reduction of NO is secondary to the 
effects of epinephrine on TNF-α and IL-10 production.  This theory rests on the idea that IL-
10 and TNF-α can influence NO activity.  Indeed, research has shown that while IL-10 
inhibits NO production, TNF-α promotes iNOS activity [37, 103].  Data from this paper 
demonstrates that epinephrine-induced reduction of NO production can be abrogated by the 
addition of anti-IL-10 in a dose-dependent manner.   The addition of exogenous TNF-α is 
also capable of a dose-dependent inhibition of epinephrine-induced reduction of NO 
production [14, 103].   Though this data provides some insight into how β-AR activity 
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modulates NO production, more work must be done to fully describe this phenomenon in a 
mechanistic manner. 
 Most reports exploring the effects of β2-AR activity upon NO production by 
macrophages employed LPS as a means of macrophage activation [14].  However, a subset 
of publications demonstrated the ability of β2-AR stimulation to inhibit NO generation by 
macrophages activated by alternative sources.  A paper by Boomershine and colleagues 
explored the effect of β2-AR activation upon NO production by Mycobacterium avium 
infected macrophages.  Data from this paper indicate that β2-AR agonists are capable of 
reducing NO production by IFN-γ-primed murine macrophages infected with Mycobacterium 
avium.  Stimulation of β2-ARs also results in the reduction of iNOS mRNA expression in 
these macrophages [6].  Data has also demonstrated that treatment with epinephrine and 
isoproterenol reduces NO production from macrophages activated in vitro by acetylated low-
density lipoproteins [56].  
 
β2-Adrenergic Receptor Anti-inflammatory Modulation of Superoxide Production. 
Reactive oxygen species (ROS), including superoxide radicals, are important 
molecules capable of promoting inflammation.  Although small in size, ROS are highly 
reactive.  This reactivity is due to the existence of unpaired valence shell electrons that 
rapidly interact with nearby molecules in an attempt to establish stability.  Throughout 
nature, ROS are formed by a variety of mechanisms.  With respect to the immune system, 
ROS are produced by neutrophils and macrophages during a process known as the 
respiratory burst.  Once released, these reactive oxygen metabolites are not only capable of 
killing foreign pathogens but also harming valuable host tissues.  As a result, the release of 
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ROS compounds must be regulated in an attempt to prevent destruction of  “innocent,” by-
stander tissues of the host.  Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
is a membrane-bound enzyme involved in the production of ROS during the respiratory 
burst.  This enzyme is made up of five components often referred to as “phox” (phagocytic 
oxidase) subunits – gp91phox, p22phox, p47phox, p67phox and p40phox.  The NADPH oxidase 
complex catalyzes a reaction that uses electrons from the cytosolic side of the plasma 
membrane to reduce extracellular oxygen (O2) to superoxide (O2•-) in the following reaction: 
 
Then, the superoxide anion can be spontaneously or enzymatically converted to other ROS 
such as hydrogen peroxide (H2O2), hypochlorous acid (HOCl), and potentially even the 
hydroxyl radical (OH•) [45, 70, 97].  
Although the antimicrobial properties of ROS produced by macrophages during the 
respiratory burst are well documented, the size of the respiratory burst is much smaller in 
macrophages than in neutrophils [45, 97].  Because of this fact, much of the work to identify 
and establish the mechanism of NADPH activation has been studied in the context of 
activated neutrophils [97].  Nevertheless, extensive research has been conducted to establish 
ways to regulate the production of ROS by macrophages [45].  Importantly, with respect to 
this thesis, the anti-inflammatory properties of β2-AR activation have encouraged the idea of 
employing β2-AR drugs as potential mediators of superoxide production by macrophages.   
Unlike the previously described studies, LPS is not typically used to induce 
superoxide production by macrophages.  In the studies discussed below, macrophages are 
either treated with phorbol 12-myristate 13-acetate (PMA) or opsonized zymosan to induce 
superoxide production.  Both of these treatments have been proven to induce superoxide 
NADPH + 2O2       NADPH Oxidase      NADP+ H+ +2O2•- 
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production by macrophages in the past [32, 33, 74].  The first paper to expand the anti-
inflammatory activities of β2-ARs to include superoxide production was published by Conlon 
et. al. in 1988.  This paper used a chemiluminescence assay to determine the effect of 
adrenergic stimulation on superoxide production by bovine pulmonary alveolar macrophages 
previously challenged with opsonized zymosan.  Results from this paper demonstrate the 
ability of the β-AR agonist, isoproterenol, to significantly reduce maximum 
chemiluminescence levels (i.e. superoxide production) in experimental groups compared to 
control groups (no β-AR treatment).   Data from experiments using the β2-AR-specific, ICI 
118,551, suggest the β2-AR subtype is responsible for the observed reduction in superoxide 
production following exposure to isoproterenol [18].    In 1991, a paper by Calhoun and 
colleagues extended these studies to include human PBMCs and alveolar macrophages.  
According to data from this publication, exposure to isoproterenol reduces PMA-induced 
superoxide production by human monocytes and macrophages in vitro [11].  Several papers 
followed confirming these early reports [13, 17, 34, 79].    One such paper explored the effect 
of isoproterenol on superoxide production by PMA-stimulated primary hamster microglial 
cells.  Again, data from this paper demonstrated that isoproterenol is capable of inhibiting 
PMA-induced superoxide production in a dose-dependent manner.  The addition of 
propranolol, a β-AR antagonist, abrogated the effect of isoproterenol on microglial 
superoxide production.  Due to the ability of β-AR activity to raise intracellular cAMP levels, 
the authors of this paper proposed this as a potential mechanism of superoxide regulation.  To 
test this hypothesis, PMA-treated microglia were exposed to forskolin, which is known to 
increase cAMP levels via adenylate cyclase activation.  Upon exposure to forskolin, 
superoxide production was reduced in a manner similar to that of isoproterenol-treated 
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microglia.  Results from these experiments suggest that cAMP levels may contribute to the 
observed effects.  It was also proposed that these cAMP-mediated events may work by 
influencing NADPH oxidase activity [20, 30, 65].  However, these authors did not go further 
into this potential mechanism of superoxide production [17]. 
 
Mechanisms of β 2-Adrenergic Receptor Anti-inflammatory Activity. 
The collection of papers discussed above demonstrates the anti-inflammatory 
properties of β2-AR activity with regard to monocyte/macrophage function.  Both 
endogenous and exogenous ligands of the β2-AR are capable of reducing LPS-induced 
production of pro-inflammatory mediators such as TNF-α, IL-1β, IL-6, etc.  Research has 
also shown that β2-AR activity promotes the production of IL-10, an anti-inflammatory 
cytokine.  It is well established that the production of various inflammatory mediators, 
especially cytokines, can be regulated at transcriptional and post-transcriptional levels.  As a 
result, there are several mechanisms by which β2-AR agonists may regulate LPS-induced 
inflammatory mediator production.  However, very little research has been done to fully 
explore the mechanisms by which β2-AR agonists exert their anti-inflammatory properties.  
The most studied mechanism of β2-AR immunomodulation focuses on the involvement of 
cAMP. 
To understand the modulatory mechanisms of β2-ARs, it is important to recall the 
canonical signaling pathway of β2-AR activation.  As shown in Figure 2.5, cAMP levels are 
elevated following activation of adenylate cyclase via the α-subunit of the Gs-protein that is 
coupled to the β2-AR.   Elevated cAMP levels lead to the activation of PKA [50, 52].  It is 
important to note that PKA is involved not only in the phosphorylation and desensitization of 
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the β2-AR but also in the phosphorylation of the cAMP-responsive element binding protein 
(CREB).  Phosphorylated CREB goes on to bind to cAMP-responsive element (CRE) sites 
present within the promoter region of several cAMP-responsive genes [75].  In addition to 
activating PKA, cAMP also stimulates other effector molecules including the guanine 
nucleotide exchange factor (GEF) known as exchange protein directly activated by cAMP 
(EPAC) [86, 89].  The involvement of EPAC in cAMP-mediated signaling will be discussed 
further in the next chapter since it is associated with pro-inflammatory activities of the β2-AR 
[86]. 
As illustrated in Figure 4.2, LPS-stimulation of monocytes and macrophages via TLR 
4 leads to the activation of NF-κB. NF-κB is an important molecular mediator of 
inflammation as it positively regulates the production of several pro-inflammatory cytokines.  
Research has demonstrated that elevated cAMP levels can inhibit NF-κB-mediated 
transcription via the PKA pathway [71].   In this pathway, PKA-mediated phosphorylation of 
CREB leads to the recruitment of CREB-binding protein (CBP).  CBP is a known coactivator 
of NF-κB and interacts with the p65 subunit of NF-κB to promote effective transcription.  As 
a result, the competition between p65 and phosphorylated CREB for CBP leads to reduced 
NF-κB activity [71, 99].  Since β2-AR stimulation upregulates cAMP, the cAMP-dependent 
PKA pathway of NF-κB regulation is a potential mechanism of β2-AR modulation (see 
Figure 4.2).  However, additional research is required to fully confirm the involvement of 
this pathway in β2-AR-mediated immunomodulation.  Another potential mechanism of β2-
AR-mediated immunomodulation involves the regulation of IκB proteins.  IκB serves to 
sequester cytoplasmic NF-κB molecules in their inactive form.  The phosphorylation and 
degradation of IκB-α leads to nuclear translocation of NF-κB.  Once within the nucleus, NF-
 90 
κB binds to responsive elements within promoter regions of various inflammatory genes.  
Several publications have demonstrated the regulation of pro-inflammatory cytokines at the 
level of IκB-α [1, 2, 26, 76, 100].   The following paragraph will review an article citing 
IκB-α regulation as a potential mechanism of β2-AR-mediated immunomodulation. 
Though β2-AR-mediated increases in cAMP have been implicated in the 
transcriptional regulation of several pro-inflammatory molecules, the mechanisms 
surrounding TNF-α production are the most studied.  In 2000, Farmer and Pugin published a 
landmark paper describing the molecular basis of TNF-α modulation by β-AR agonists in 
monocytic cells.  In this paper, the authors demonstrated the ability of β-AR agonists to 
reduce TNF-α production via a NF-κB-dependent pathway.  Treatment of LPS-induced 
THP-1 human monocytic cells with the β-AR agonist, isoproterenol, inhibited translocation 
of NF-κB (3 h post β-AR treatment).  Isoproterenol did not alter IκB-α levels initially.  
However, 3 h after isoproterenol treatment, IκB-α protein levels were significantly increased.  
The use of H-89, an inhibitor of cAMP-dependent PKA, blocked the observed effects of 
isoproterenol.  Data from this paper also demonstrated that isoproterenol treatment, in the 
absence of LPS-co-stimulation, did not increase IκB-α levels.  These results indicate that 
LPS is responsible for some part of this signal.  Previous reports have shown that the IκB-α 
gene includes a κB site.  Therefore, LPS-induced NF-κB activity may auto-regulate IκB-α 
gene expression [9, 15].   Importantly, Farmer and Pugin noted that IκB-α exhibited an 
increased half-life in isoproterenol-treated THP-1 cells.  Based on these results, the authors 
theorized that LPS and β2-AR agonists work together to increase IκB-α levels and inhibit 
NF-κB activity.  This theory proposes that while LPS may initially play a role in increasing 
IκB-α transcription, β2-AR activity stabilizes these newly synthesized IκB-α molecules (see 
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Figure 4.2).  As a result, IκB-α levels accumulate, and NF-κB activity is inhibited.  The 
exact mechanism by which this occurs is not fully defined [26]. 
 
Biological Relevance and Future Directions. 
 As mentioned earlier, β2-AR activity is involved in a variety of physiologically 
relevant processes during periods of health and disease.   Of importance to this thesis is the 
involvement of catecholamines during various inflammatory conditions.  It is widely 
accepted that endogenous catecholamine levels rise during systemic inflammation.  
Additionally, exogenous sources of catecholamines and adrenergic drugs are often 
administered to treat various disease processes including asthma, chronic obstructive 
pulmonary disorder and sepsis.  Although adrenergic drugs are known influence the immune 
response, these drugs are not readily used as anti-inflammatory agents. The publications 
discussed throughout this chapter promote the anti-inflammatory properties of β2-AR 
stimulation.  Indeed, these papers provide the evidence necessary to suggest using β2-AR 
drugs to treat various inflammatory conditions. 
 Though there is abundant evidence to support the anti-inflammatory role of β2-AR 
agonists, additional studies must be done to fully characterize these effects.  To begin, as 
with any collection of work, there are variations present throughout these reports.  These 
variations may be due to several factors including ligand choice, cell type/source, 
experimental conditions, etc.  For instance, studies have shown that ligand classification 
(short- vs. long- acting) and ligand-receptor stereoselectivity influence the anti-inflammatory 
activity of β2-AR agonists [36, 48, 51].  The anti-inflammatory properties of β2-AR 
stimulation are also influenced by cell type.  According to several lines of research, 
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monocytes, when compared to macrophages, are often more responsive to the anti-
inflammatory effects of β2-AR stimulation. This variation is thought to be the result of 
decreased expression of β2-ARs by macrophages in comparison to monocytes [51]. The 
effects of β2-AR stimulation may also be influenced by cell source (primary vs. cell line/ 
human vs. other species).  Furthermore, experimental conditions such as concentration, time 
course and duration of exposure (to β2-AR agonists and the given co-stimulus) can greatly 
influence the anti-inflammatory effects of β2-AR stimulation upon monocytes/macrophage 
response [51, 78].  As many (or all) of these factors may influence β2-AR agonist activity, 
more research must be done to better define their impact upon the anti-inflammatory effects 
of β2-ARs. 
As indicated by the lack of publications, another area requiring additional research is 
identifying the signaling pathways responsible for the anti-inflammatory activities of β2-AR 
agonists.  Although many publications have suggested potential pathways of mediation, very 
few investigators have extended their theories into experimental evidence.  The fact that 
cytokines and other inflammatory mediators can be regulated on a variety of levels (i.e. 
transcriptional, post-transcriptional, etc.) introduces multiple pathways of investigation.  In 
2000, Farmer and Pugin took existing research a step further by actually exploring the 
signaling pathway involved in β2-AR modulation of TNF-α production.  This paper 
confirmed earlier theories involving cAMP, PKA and NF-κB activity [26].  However, there 
are still areas that need clarification in this pathway – especially with respect to LPS/β2-AR-
mediated IκB-α regulation.  Though Farmer and Pugin identified the signaling pathway 
involved in β2-AR modulation of TNF-α production by monocytes, this pathway may not 
hold true for other inflammatory mediators.  As a result, extensive research must be done to 
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fully define the various signaling cascades involved in β2-AR-mediated modulation of 
inflammatory mediators including IL-1β, IL-6, IL-10, MIP-1α, NO and superoxide.  
 
Summary. 
For years, the immunomodulatory capacities of catecholamines and adrenergic drugs 
have been recognized by the scientific world.  Studies exploring the effect of β2-AR 
stimulation upon the production of various inflammatory mediators have deemed β2-AR 
agonists as anti-inflammatory agents (see Figure 4.1).  Since monocytes and tissue 
macrophages are a large source of these inflammatory mediators, many investigators have 
focused on defining the immunomodulatory effects of β2-AR activity on this particular subset 
of cells.   Indeed, several papers have been published exploring the β2-AR-mediated 
modulation of LPS-induced TNF-α, IL-1β, IL-6, IL-10, MIP-1α, NO and superoxide 
production by monocytes and macrophages.  Although many publications have confirmed the 
anti-inflammatory properties of β2-AR agonists upon macrophage response, additional 
research is required to fully characterize these effects.  Nevertheless, given the appropriate 
conditions, the potential to use β2-AR agonists as anti-inflammatory drugs remains 
promising.  
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FIGURE 4.1 
 
FIGURE 4.1 – Summary of Anti-inflammatory Effects of β2-Adrenergic Receptors upon 
Inflammatory Mediator Production by Macrophages.  Throughout time, several papers 
have been published demonstrating the anti-inflammatory activities of β2-AR stimulation 
upon macrophage inflammatory mediator production.  In most cases, β2-AR stimulation 
experiments were conducted in conjunction with a known co-stimulatory molecule such as 
LPS.  *Experiments conducted to determine the effect of β2-AR stimulation upon superoxide 
production were conducted using PMA or opsonized zymosan as a co-stimulatory source.  
 95 
 
 
FIGURE 4.2   
   
 
 
 
 
 
 
 
FIGURE 4.2 – Anti-inflammatory modulation of LPS-induced cytokine production by 
β2-Adrenergic Receptor Stimulation.  (A) LPS activation of macrophages leads to the 
upregulation of pro-inflammatory cytokines via activation of NF-κB.  This occurs following 
the phosphorylation of IκB-α by the IKK complex.  Phosphorylated IκB-α is degraded and 
NF-κB is free to translocate to the nucleus.  Once within the nucleus, NF-κB associates with 
co-activators such as CBP or p300 and transcription commences.  (B) β2-AR stimulation leads 
to the activation of PKA.  PKA phosphorylates CREB.  Phosphorylated CREB recruits CBP, 
which is also a co-activator of NF-κB.  Phosphorylated CREB competes with NF-κB for a 
limited amount of CBP.  The competition for limited quantities of CBP is theorized to result 
in decreased NF-κB activity and reduced cytokine production.  (C) β2-AR stimulation has 
been shown to increase cytoplasmic levels  and the half life of IκB-α.  Since IκB-α is a 
natural inhibitor of NF-κB activity, β2-AR-induced increases in IκB-α levels are theorized to 
result in reduced NF-κB activity and pro-inflammatory cytokine production.  The signaling 
mechanism responsible for the increased levels of IκB-α is undefined but is believed to be 
PKA-dependent [1, 4, 26, 28]. 
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CHAPTER V:  PRO-INFLAMMATORY MODULATION OF MACROPHAGE 
RESPONSE BY β2-ADRENERGIC RECEPTOR ACTIVITY 
 
 
 
 Traditionally, activation of β2-ARs has been reported to possess anti-inflammatory 
effects upon the immune response [20, 40, 42, 49].  However, a thorough survey of existing 
literature reveals a small subset of publications describing the pro-inflammatory activities of 
β2-ARs located on monocytes and macrophages.  These papers have focused on the ability of 
β2-ARs to induce the production of several inflammatory mediators including TNF-α, IL-1β, 
IL-6, and NO [8, 47-49].  Though data from these reports endorse the pro-inflammatory 
potential of β2-ARs, this concept is relatively new and has not been fully characterized.  The 
contents of this chapter will provide a comprehensive review of existing literature concerning 
the pro-inflammatory effects of β2-AR stimulation on inflammatory mediator production by 
monocytes and macrophages. 
 
β2-Adrenergic Receptor Pro-inflammatory Modulation of Cytokine Production. 
As described in previous chapters, the immune response is influenced by β2-AR-
mediated immunomodulation.  Since monocytes and macrophages express β2-ARs and are 
major sources of cytokine production, many researchers have sought to identify the effects of 
β2-AR stimulation upon these cells.  Accepted dogma dictates that β2-ARs exert anti-
inflammatory effects upon cells of the immune system.  Indeed, there is abundant
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evidence (in vitro and in vivo) to support the anti-inflammatory properties of β2-AR 
stimulation [15, 20, 23, 26, 42].  Though the anti-inflammatory model of β2-AR activity 
appears deeply entrenched throughout science, research has demonstrated that the 
physiological role of the β2-AR is actually quite diverse [24, 48].  These functional variations 
often reflect the myriad of conditions under which the β2-ARs are activated.  With this in 
mind, several investigators have focused on examining the pleotropic immunomodulatory 
effects of β2-AR activating agents on numerous cell types under a variety of environmental 
conditions.  For instance, studies have shown that activation of β2-ARs found on myocytes, 
pituicytes, adipocytes, cardiac fibroblasts and skeletal muscle cells promoted the 
upregulation of the pro-inflammatory cytokine, IL-6 [10, 18, 30, 36, 50].  Additionally, 
Krishnaswamy and colleagues have demonstrated that activation of β2-ARs on mast cells 
lead to increased IL-13 mRNA production [7].  Importantly, for the purpose of this thesis, 
these papers have encouraged additional papers exploring the pro-inflammatory effects of β2-
ARs upon cells of the mononuclear phagocyte system. 
 Surprisingly, many of the original papers aimed at characterizing the anti-
inflammatory actions of β2-ARs on monocytes and macrophages actually provided evidence 
to suggest a pro-inflammatory role for these receptors as well.  For example, careful 
examination of the 1992 paper by Severn and colleagues reveals an intriguing, pro-
inflammatory caveat within their data.  This study characterized the effect of epinephrine and 
isoproterenol upon TNF-α production by LPS-treated THP-1 monocytes.  In most cases, 
epinephrine/isoproterenol significantly reduced TNF-α production by LPS-treated cells.  
However, a 24-h pre-treatment with epinephrine actually led to a significant increase in LPS-
induced TNF-α production.  As described earlier in chapter four, this pro-inflammatory 
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effect was attributed to reduced cAMP levels and/or epinephrine-induced receptor 
desensitization.  Though these studies suggest the involvement of cAMP, the signaling 
mechanism responsible for the observed pro-inflammatory phenomenon was not defined by 
Severn and colleagues [40].  In 1999, Nakamura and colleagues published a paper that also 
demonstrated the dual immunomodulatory potential of β-AR activation upon macrophages.  
This set of experiments used LPS-stimulated renal macrophages to study the modulatory 
effect of β2-AR agonists upon IL-6 production.  In this paper, Nakamura et. al. demonstrate 
that β2-AR activation (at varying concentrations) had a “biphasic” effect on IL-6 production.  
Data from these studies demonstrate that while high concentrations (10-6 M) of the β2-AR 
agonist, tertbutaline, enhanced LPS-induced IL-6 production, lower concentrations (10-8 M) 
of the agonist significantly reduced IL-6 production by LPS-stimulated macrophages.  In an 
attempt to explain this “biphasic” phenomenon, several potential modulatory mechanisms 
were explored.  Based on data from their studies, Nakamura and colleagues propose that the 
β2-AR-mediated downregulation of IL-6 production was secondary to the inhibitory effect of 
tertbutaline upon TNF-α production.  However, no TNF-α inhibitory experiments were 
conducted to confirm this mechanistic theory.  Nakamura et. al. attributed the β2-AR-
mediated upregulation of LPS-induced IL-6 production to increases in cAMP levels.  The 
proposed cAMP/PKA-dependent signaling cascade was supported by the fact that treatment 
with H-89, a PKA inhibitor, prevented β2-AR-induced increases in IL-6 production [32, 51].  
Although the regulatory mechanisms proposed by Nakamura et. al. are complex and require 
additional work for clarification, these studies demonstrate that stimulation of β2-ARs can 
elicit both pro- and anti-inflammatory outcomes [32].  In conclusion, data from the 
publications discussed above promote the importance of recognizing how environmental 
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factors, such as time/duration of treatment and concentration of agonist, can influence the 
effects of β2-AR activation upon cytokine production.   
 Another factor to consider is the co-stimulatory environment under which the β2-AR 
is activated.  A review of current literature reveals that the immunomodulatory properties of 
β2-ARs are almost always studied in conjunction with a known immune activator such as 
LPS.  This co-stimulatory experimental model was designed based on the fact that β2-AR 
agonists are often administered to treat complications (blood pressure, irregular cardiac 
function, etc.) associated with systemic inflammatory conditions such as bacterial 
endotoxemia and septicemia.  However, there are instances when β2-ARs may be stimulated 
in the presence of a co-stimulatory molecule other than LPS (i.e. cytokines, microbial by-
products, viral components).  Recently, Szelenyi and colleagues published a paper exploring 
the effect of variable co-stimulatory environments upon β-AR inflammatory activity.   In this 
paper, the authors compare the immunomodulatory effect of isoproterenol, a β-AR specific 
agonist, upon TNF-α, IL-12 and NO production by LPS- or PMA-stimulated monocytes and 
macrophages.  To begin, results from this study confirm previous reports demonstrating that 
β-AR stimulation decreased inflammatory mediator production by LPS-treated cells.  
Treatment of PMA-stimulated macrophages with isoproterenol, on the other hand, actually 
led to increases in TNF-α, IL-12 and NO production.  Importantly, these studies were 
repeated using the β2-AR-specific agonist, clenbuterol. Results from these experiments were 
similar to those conducted using isoproterenol suggesting that the β2-AR subtype may be 
responsible for these dual immunomodulatory actions.   
According to data from Szelenyi’s paper, co-stimulatory environments greatly 
influence the immunomodulatory potential of β-AR activation.  This paper also explored the 
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signaling mechanisms responsible for the co-stimulus-dependent regulation of TNF-α, IL-12 
and NO production by β-ARs.  Since MAPKs are known to regulate cytokine and NO 
production, Szelenyi and colleagues explored the effects of β-AR agonists upon LPS- and 
PMA-induced pERK and p38 activity [9, 16, 19].  Results from these experiments reveal that 
the dual effects of isoproterenol on LPS- and PMA-treated cells were paralleled by 
differences in pERK and p38 phosphorylation.  More specifically, while treatment with 
isoproterenol increased MAPK phosphorylation of PMA-stimulated macrophages, β-AR 
stimulation of LPS-treated cells resulted in reduced levels of MAPK phosphorylation.  The 
data from these studies were in accordance with other publications reporting that MAPK 
inhibitors can modulate various inflammatory diseases [25, 47].  Notably, a paper by Feng et. 
al. demonstrates that cAMP elevators were capable of inhibiting LPS-induced IL-12 
production via inhibition of the p38 MAPK pathway [16].  Since β-AR stimulation is known 
to elevate cAMP levels, Szelenyi et. al. theorize that this pathway may be responsible for the 
isoproterenol-induced reduction in LPS-mediated MAPK phosphorylation.  Furthermore, the 
β-AR-mediated increases in PMA-induced ERK and p38 phosphorylation are believed to be 
responsible for the increases in TNF-α, IL-12 and NO production in these cells.  Taken 
together, Szelenyi and colleagues propose that MAPKs behave as “molecular switches” that 
regulate β-AR immunomodulation according to which co-stimulatory molecule is applied.  
Though more work is required to fully characterize the β-AR signaling mechanisms 
responsible for these effects, the idea that β-AR agonists may wield dual modulatory effects 
(depending on the co-stimulatory environment) introduces an additional layer of complexity 
with regard to their use as therapeutic agents [47]. 
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 In addition to being stimulated in combination with a variety of immune activators, it 
is possible that the activation of β2-ARs may occur in the absence of additional stimuli.  For 
instance, β2-AR agonists are often administered to treat patients with asthma.  As a result, 
macrophages in the airways are often exposed to β2-AR agonists in the absence of LPS 
and/or other co-stimulatory molecules.  Activation of β2-ARs may also occur by endogenous 
ligands in the absence of other stimulatory agents.  An example of this phenomenon would 
be the activation of β2-ARs by circulating catecholamines in patients suffering from chronic 
stress.  Several studies have shown chronic stress increases susceptibility to various illnesses 
including peptic ulcers, ulcerative colitis, viral infections, asthma, myocardial infarction and 
depression.  It has been proposed that the increased levels of circulating catecholamines 
associated with chronic stress may be responsible for influencing the patient’s immune 
system and, therefore, their susceptibility to these conditions [14, 34].  Because it is possible 
that β2-ARs may be stimulated in the absence of an additional co-stimulatory molecule, it is 
important to study the effect of β2-AR agonists alone upon cytokine production. 
In 1995, Tomozawa and colleagues published one of the earliest papers exploring the 
effect of β-AR stimulation upon cytokine production in the absence of a co-stimulus.  This 
study explored the effect of isoproterenol on IL-1β mRNA production by primary rat 
microglial cells.  A Northern blot analysis of microglial IL-1β mRNA production revealed 
that β-AR stimulation increased IL-1β mRNA levels in a dose-dependent manner.   It is 
important to note that although IL-1β mRNA levels were increased following isoproterenol 
treatment, Tomozawa failed to explore the effect of β-AR stimulation on IL-1β at the protein 
level.  Additionally, the increases in IL-1β mRNA were paralleled by increases in cAMP 
levels.  Based on this data, Tomozawa et. al. proposed that β-AR-induced increases in IL-1β 
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mRNA may be mediated by a cAMP-dependent PKA pathway.  This theory was supported 
by the fact that H8, a cAMP-dependent protein kinase inhibitor, blocked isoproterenol-
induced upregulation of IL-1β production [49].  However, a recent paper by Tan et. al. 
presents data that opposes the cAMP/PKA-dependent mechanistic theory put forth by 
Tomozawa [48, 49].   
In their 2006 publication, Tan and colleagues explore the effect of salmeterol, a β2-
AR-specific agonist, upon IL-1β and IL-6 production by RAW 264.7 murine macrophages.  
Data from these experiments demonstrate that stimulation of β2-ARs by salmeterol increases 
IL-1β and IL-6 production by RAW 264.7 macrophages and other cells belonging to the 
monocytic lineage (J774A.1 macrophages, THP-1 monocytes and BV2 microglia).  These β2-
AR-mediated increases were observed at both the mRNA and protein level.  Furthermore, 
exposure of macrophages to ICI 118,551, a β2-AR-specific antagonist, inhibited salmeterol-
induced increases in IL-1β and IL-6.  Based on current literature, Tan et. al. initially 
proposed a signaling mechanism that involved the cAMP-dependent activation of PKA.  
Once activated, it was theorized that PKA would phosphorylate CREB, which would then 
bind to CRE sites present in the promoter regions of IL-1β and IL-6 [6, 28, 35, 37].  To 
determine if β2-AR stimulation mediates pro-inflammatory cytokine production via the 
cAMP/PKA/CREB cascade, Tan and colleagues conducted several experiments using 
various PKA inhibitors (H89, KT5720 and RP-cAMP).  Results from this set of experiments 
demonstrate that treatment with H89, KT5720 and RP-cAMP had no effect upon β2-AR-
mediated increases in IL-1β and IL-6 production.  It is important to note that Tan and 
colleagues also conducted studies using NF-κB inhibitors to demonstrate that NF-κB is not 
involved in mediating β2-AR-induced increases in IL-1β and IL-6.  This data, which does not 
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agree with the data from Tomozawa et. al., suggests that pro-inflammatory cytokine 
production following β2-AR activation is not mediated via the cAMP/PKA/NF-κB signaling 
cascade.  
 Recently, research has indicated that cAMP is capable of activating several 
molecules (other than PKA) including the guanine nucleotide exchange factor for Rap1 
known as EPAC [13].  This prompted Tan and colleagues to explore the involvement of 
EPAC in mediating the pro-inflammatory effects of salmeterol.  Results from these studies 
indicate that activation of EPAC increases IL-1β and IL-6 production and may contribute to 
the pro-inflammatory effects of β2-AR stimulation.  Since β2-AR activity is also known to 
activate MAPKs via Gs-dependent and Gs-independent mechanisms, Tan et. al. sought to 
determine if MAPKs are involved in mediating the pro-inflammatory activities of salmeterol 
[3, 12, 38].  Experiments using ERK 1/2, JNK and p38 MAPK inhibitors demonstrate that 
inhibition of ERK 1/2 and p38 (but not JNK) MAPKs blocked β2-AR-induced increases in 
IL-1β and IL-6 production.  Tan and colleagues also show that increased phosphorylation of 
ERK 1/2 and p38 occurred following salmeterol treatment.  Due to the ability of the 
EPAC/Rap1/B-raf pathway to activate MAPKs, the next step was to determine if this 
pathway was involved in the β2-AR-mediated induction of ERK 1/2 and p38 activity [13, 
22].  Experiments using a B-raf inhibitor indicate that β2-AR-induced B-raf activity is 
required for the increases in IL-1β and IL-6 following exposure to salmeterol.  Finally, Tan 
and colleagues conducted experiments to determine the transcription factors responsible for 
β2-AR-induced increases in cytokine production by macrophages.  Because stimulation of 
ERK 1/2 and p38 activates the CREB, activating transcription factor (ATF), 
CCAAT/enhancer-binding protein beta (C/EBPβ), and/or E-twenty-six (ETS) family of 
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transcription factors, Tan et. al. explored the involvement of these molecules in mediating the 
pro-inflammatory effects of salmeterol.  Results from this set of studies demonstrate that 
ATF-1 and ATF-2 transcription factors are involved in mediating the increases in IL-1β and 
IL-6 production following β2-AR stimulation.  Taken together, Tan and colleagues have 
shown that the pro-inflammatory activities of β2-ARs are not mediated by the 
cAMP/PKA/NF-κB pathway as initially expected.  Instead, these effects are mediated via the 
ERK 1/2 and p38 signaling pathways (See Figure 5.2).   
 
β2-Adrenergic Receptor Pro-inflammatory Modulation of Nitric Oxide Production. 
 As discussed in chapter four, NO is a multi-functional molecule that can act as a 
vasodilator, neurotransmitter and inflammatory mediator.   Years of research have shown that 
although NO is a vital component of the immune response, excessive NO production during 
infection can severely damage valuable host tissues [8, 17, 21, 45].  Importantly, many cells 
produce NO including cells of the monocytic lineage.  NO is synthesized from the oxidation 
of L-arginine by one of three forms of NOS – eNOS (endothelial), nNOS (neuronal) or iNOS 
(inducible) [17].  Macrophages express the iNOS form of this molecule, which can be 
induced following exposure to various cytokines, microbes and/or microbial products such as 
LPS [8, 17].  For years, scientists have recognized the modulatory properties of β2-AR 
stimulation with regard to NO production.  Though β2-AR modulation of NO production is 
generally considered anti-inflammatory in nature, there are several publications that suggest 
otherwise [8, 44, 46].  Recently, research has shown that macrophages isolated from stressed 
mice produced higher levels of NO following LPS-stimulation in vitro than non-stressed 
mice.  This data suggests that stress is capable of modulating LPS-induced NO production.  
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More specifically, it has been proposed that catecholamines are responsible for the observed 
stress-induced modulation of NO production by monocytes and macrophages [8, 41].  
 In 2003, Chi et. al. published a paper describing the pro-inflammatory effects of β-
AR stimulation upon LPS-induced NO production by RAW 264.7 macrophages.  Data from 
these studies demonstrate that both epinephrine and norepinephrine enhanced LPS-induced 
NO production in a dose-dependent fashion.  Studies exploring LPS-induced iNOS 
expression also showed a dose-dependent increase with respect to epinephrine/ 
norepinephrine treatment.  Furthermore, the use of a β-AR-specific antagonist (propranolol) 
significantly reduced the enhancing effects of these catecholamines upon LPS-induced iNOS 
and NO levels.  Taken together, this data indicates that β-ARs are responsible for the 
observed effects. [8].  However, Chi and colleagues did not explore the signaling 
mechanisms responsible for the pro-inflammatory effects of epinephrine and norepinephrine 
upon NO production.  
 Data from the 2005 publication by Lin et. al. also demonstrates the pro-inflammatory 
activities of β-ARs with regard to NO production.  To begin, this study explored the effects 
of epinephrine/norepinephrine upon LPS-induced NO and iNOS levels.  Again, exposure to 
epinephrine/norepinephrine significantly increased both LPS-induced iNOS expression and 
NO production by RAW 264.7 murine macrophages.  Furthermore, treatment with a β-AR 
antagonist was capable of blocking these effects.  Next, Lin and colleagues advanced their 
studies by proposing a mechanism responsible for the catecholamine-induced increases in 
NO production.  This theory hinges on the ability of catecholamines to modulate the cellular 
uptake of L-arginine by LPS-stimulated macrophages.  As mentioned earlier, NO is produced 
by the oxidation of L-arginine by NOS activity.  Years of research have demonstrated that 
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the cellular uptake of L-arginine is an important regulatory mechanism associated with the 
production of NO by iNOS [27, 31].  Importantly, data from this paper demonstrates that 
catecholamine-induced increases in NO production were paralleled by increases in L-
arginine transport.   Importantly, cellular uptake of L-arginine is mediated by the 
transmembrane transport system y+, which is encoded by the cationic amino acid transporter 
(cat) genes, CAT-1 and CAT-2 [4, 27].  Indeed, members of the CAT isozyme family (CAT-
1, CAT-2, CAT-2A and CAT-2B) are required for transmembrane transport of L-arginine.  
Because studies have shown that CAT-2 and CAT-2B are involved in LPS-induced NO 
production by macrophages, Lin et. al. theorized that β-AR activity may enhance CAT-2 and 
CAT-2B expression [33, 39].  Surprisingly, treatment with epinephrine/norepinephrine had 
no effect upon LPS-induced CAT-2 or CAT-2B expression.  Instead, catecholamine 
treatment increased the expression of the constitutively expressed CAT-1 and CAT-2A 
isozymes.  However, Lin and colleagues did not perform inhibition experiments to confirm 
the involvement of the molecules in mediating catecholamine-associated increases in LPS-
induced NO production.  Therefore, more experiments are required to clarify this 
mechanism.  Lin et. al. also theorize about the involvement of NF-κB in mediating 
catecholamine-induced increases in NO production.  This theory is based on the fact that NF-
κB is a known transcription factor for a variety of inflammatory molecules including iNOS 
[5, 27].  Research has also implicated NF-κB activity in mediating the expression of CAT 
isozymes [2, 11].  Although experiments employing dexamethasone, a NF-κB inhibitor, 
suggest that NF-κB may be involved in mediating catecholamine-induced increases in NO 
production by RAW 264.7 macrophages, additional experiments must be done to fully 
characterize this signaling pathway [27].  
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Biological Relevance and Future Directions. 
 Recognition of the dual modulatory activities of β2-ARs with respect to macrophage 
function has significantly advanced the understanding of adrenergic immunomodulation. 
Historically, β2-AR signaling has been revered as having immunosuppressive effects upon 
the immune response. The papers discussed in this chapter not only challenge the accepted 
dogma regarding β2-AR activity but also introduce potential opportunities for novel 
therapeutic approaches.  It is important to recognize that, under certain conditions, β2-AR 
target therapy may actually exacerbate the very conditions they are supposed to improve.  A 
perfect example of this would be the use of β2-AR agonists as bronchodilating agents to 
provide acute relief for asthma patients.  Theoretically, the anti-inflammatory activity of β2-
ARs would also benefit the asthma-associated inflammation of the airways by inhibiting pro-
inflammatory cytokine production by resident cells of the respiratory system, especially 
macrophages.  However, research has shown that extended use of these drugs may actually 
worsen the condition by prolonging asthmatic activity, increasing airway reactivity and 
aggravating airway inflammation [1, 29, 43].  In these instances, β2-ARs may actually be 
exacerbating the inflammatory response of alveolar macrophages.  The paper by Tan et. al.  
propose that different pathways are responsible for the β2-AR-mediated bronchodilatory and 
pro-inflammatory effects.  While bronchodilation occurs via the classical β2-AR-mediated 
cAMP/PKA/CREB pathway,  the pro-inflammatory effects of β2-AR agonists are mediated 
by the cAMP/PKA/CREB-independent, ERK 1/2- and p38-dependent signaling cascade.  As 
a result, Tan and colleagues suggest that β2-AR target therapy can be improved by selectively 
blocking the pro-inflammatory side effects of β2-AR activation.  This could be done using 
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MAPK inhibitors or novel β2-AR drugs that selectively activate the cAMP/PKA/CREB 
pathway (but not the β2-AR/MAPK pathway) [48]. 
 Though the subset of papers described in this chapter established a strong foundation 
to support the pro-inflammatory potential of β2-AR activity, more research must be done to 
fully characterize these effects.  For instance, several studies are needed to expound upon 
what is currently known about β2-AR-mediated increases in TNF-α, IL-1β, IL-6, and NO 
production by monocytes and macrophages.  Furthermore, additional research is required to 
explore the pro-inflammatory effects of β2-AR stimulation on the production of other 
inflammatory mediators such as IL-10, MIP-1α, ROS, etc.  Certainly, the signaling 
mechanisms associated with both the pro- and anti-inflammatory activities of β2-ARs deserve 
more attention.  By understanding the nature of these mechanisms, scientists are more likely 
to develop novel, more effective β2-AR targeted therapies.  It would also be interesting to 
fully define the effects of different co-stimulatory molecules on the dual inflammatory 
activities of β2-ARs.  These studies would be physiologically relevant since β2-ARs are 
known to be stimulated under a variety of conditions during periods of health and disease.  If 
the situations under which β2-AR activation would result in pro-inflammatory vs. anti-
inflammatory activities were clearly defined,  clinicians would be better suited to determine 
whether or not certain β2-AR therapies should be used.  
 
Summary. 
Years of research have established that β2-AR activity influences immune cell function.  The 
stimulation of β2-ARs present on monocytes and macrophages is generally considered to 
result in the downregulation of inflammatory mediator production.  However, several papers 
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have recently demonstrated that β2-AR stimulation may increase the production of pro-
inflammatory mediators (see Figure 5.1).  A review of these papers suggests that several 
factors may be involved in dictating the immunomodulatory effects of β2-AR stimulation 
upon inflammatory mediator production by monocytes and/or macrophages. Recognizing the 
dual immunomodulatory capacity of β2-ARs is essential to understanding the pleiotropic 
effects of these receptors upon the immune system. Indeed, the dual immunomodulatory 
properties of β2-AR activation introduce an additional layer of complexity with regard to 
receptor function.  Furthermore, in order to optimize the therapeutic potential of β2-AR 
drugs, it is imperative to recognize both the pro- and anti-inflammatory activities of these 
receptors.   
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FIGURE 5.1 
 
 
 
 
 
 
 
 
FIGURE 5.1 – Summary of Pro-inflammatory Effects of β2-Adrenergic Receptors upon 
Inflammatory Mediator Production by Macrophages.  Several papers have been published 
describing the pro-inflammatory activity associated with β2-AR stimulation found on cells of 
the mononuclear phagocytic family.  The majority of these studies were done in the absence 
of a co-stimulatory molecule.  *Nitric Oxide experiments were conducted in the presence of 
LPS as described in the body of this thesis [8, 32, 46, 47, 48, 51].  
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FIGURE 5.2 
 
 
 
 
FIGURE 5.2 – Pro-inflammatory Signaling Associated with β2-Adrenergic Receptor 
Stimulation of Macrophages.  The pro-inflammatory activities of β2-AR immunomodulation 
are mediated via a PKA-independent pathway.  Following stimulation of the β2-AR receptor, 
cAMP activates EPAC, which leads to the activation of B-raf/Rap-1.  Ultimately, the ERK 
1/2 and p38 MAPK pathways are initiated, leading to the activation of ATF-1 and ATF-2 and 
the transcription of pro-inflammatory cytokines  [24, 48]. 
 
 
Adapted by permission from Elsevier Ltd: [Journal of Allergy and Clinical Immunology] 
Johnson, M. Molecular mechanisms of β2-adrenergic receptor function, response, and 
regulation. J Allergy Clin Immunol 17:18-24. © 2006. 
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